

Piotr Ponikowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4019717/publications.pdf>

Version: 2024-02-01

860
papers

242,907
citations

⁶⁶

174
h-index

¹¹

476
g-index

910
all docs

910
docs citations

910
times ranked

104729
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of an outpatient intervention comprising nurse-led non-invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (<scp>AMULET</scp> study): a randomised controlled trial. <i>European Journal of Heart Failure</i> , 2022, 24, 565-577.	2.9	23
2	Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design. <i>Advances in Medical Sciences</i> , 2022, 67, 18-22.	0.9	7
3	Valsalva-derived Measures and Phenylephrine Test in Patients With Heart Failure With Reduced Ejection Fraction Receiving Comprehensive Neurohormonal Blockade Drug Therapy: A 5-year Event-free Survival Analysis. <i>Journal of Cardiac Failure</i> , 2022, 28, 744-755.	0.7	1
4	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 24-34.	5.5	40
5	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <scp>DAPA-HF</scp>. <i>European Journal of Heart Failure</i> , 2022, 24, 513-525.	2.9	33
6	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2022, 145, 184-193.	1.6	106
7	Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 52-64.	1.9	10
8	Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the <scp>BIOSTAT-HF</scp> study. <i>European Journal of Heart Failure</i> , 2022, 24, 192-204.	2.9	20
9	Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 308-320.	2.9	9
10	Hemosiderin Accumulation in Liver Decreases Iron Availability in Tachycardia-Induced Porcine Congestive Heart Failure Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1026.	1.8	4
11	Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 431-441.	2.9	67
12	Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in <scp>DAPA-HF</scp>. <i>European Journal of Heart Failure</i> , 2022, 24, 1066-1076.	2.9	28
13	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	2.9	820
14	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF. <i>JACC: Heart Failure</i> , 2022, 10, 104-118.	1.9	5
15	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 228-239.	2.2	4
16	Early Hemodynamic Changes following Surgical Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction. <i>Journal of Clinical Medicine</i> , 2022, 11, 1063.	1.0	2
17	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. <i>Nature Medicine</i> , 2022, 28, 568-574.	15.2	341
18	Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>JACC Asia</i> , 2022, , .	0.5	2

#	ARTICLE	IF	CITATIONS
19	Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, 24, 821-832.	2.9	15
20	Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 782-790.	2.9	16
21	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. <i>Clinical Research in Cardiology</i> , 2022, 111, 912-923.	1.5	10
22	Responder analysis for improvement in six-minute walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, .	2.9	8
23	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008970.	1.6	8
24	Relationship of Dapagliflozin With Serum Sodium. <i>JACC: Heart Failure</i> , 2022, 10, 306-318.	1.9	10
25	Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. <i>Circulation</i> , 2022, 146, 279-288.	1.6	65
26	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2022, 43, 863-867.	1.0	14
27	Contribution of Peripheral Chemoreceptors to Exercise Intolerance in Heart Failure. <i>Frontiers in Physiology</i> , 2022, 13, 878363.	1.3	2
28	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. <i>Circulation</i> , 2022, 146, 438-449.	1.6	53
29	Clinical implications of low estimated protein intake in patients with heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, .	2.9	7
30	Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. <i>Annals of Internal Medicine</i> , 2022, 175, 820-830.	2.0	56
31	Biomarkers of Myocardial Injury and Remodeling in Heart Failure. <i>Journal of Personalized Medicine</i> , 2022, 12, 799.	1.1	13
32	Novel Biomarkers of Renal Dysfunction and Congestion in Heart Failure. <i>Journal of Personalized Medicine</i> , 2022, 12, 898.	1.1	2
33	Induction of Day-Time Periodic Breathing is Associated With Augmented Reflex Response From Peripheral Chemoreceptors in Male Patients With Systolic Heart Failure. <i>Frontiers in Physiology</i> , 2022, 13, .	1.3	0
34	Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	10
35	Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF. <i>JACC: Heart Failure</i> , 2022, 10, 651-661.	1.9	9
36	Novel Phenotyping for Acute Heart Failure—Unsupervised Machine Learning-Based Approach. <i>Biomedicines</i> , 2022, 10, 1514.	1.4	8

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1614-1622.	2.9	15
38	Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1-18.	1.2	21
39	Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients. <i>European Journal of Heart Failure</i> , 2021, 23, 729-739.	2.9	32
40	High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. <i>European Journal of Heart Failure</i> , 2021, 23, 919-932.	2.9	46
41	Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe. <i>American Journal of Medicine</i> , 2021, 134, 482-489.	0.6	53
42	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 298-309.	1.6	193
43	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 117-128.	13.9	1,080
44	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	13.9	381
45	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. <i>Circulation</i> , 2021, 143, 337-349.	1.6	217
46	Effects of a Novel Nitroxyl Donor in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 146-157.	1.9	17
47	Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2021, 23, 43-57.	2.9	19
48	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF ² study. <i>European Journal of Heart Failure</i> , 2021, 23, 58-67.	2.9	10
49	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 1203-1212.	1.0	114
50	Prediction of AF in Heart Failure With Preserved Ejection Fraction. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 131-144.	2.3	25
51	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-CHF. <i>European Journal of Heart Failure</i> , 2021, 23, 632-643.	2.9	24
52	Antiplatelets in acute coronary syndrome in Poland – from guidelines to clinical practice. <i>Postępy W Kardiologii Interwencyjnej</i> , 2021, 17, 141-154.	0.1	2
53	Nurse-led ambulatory care supported by non-invasive haemodynamic assessment after acute heart failure decompensation. <i>ESC Heart Failure</i> , 2021, 8, 1018-1026.	1.4	8
54	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. <i>ESC Heart Failure</i> , 2021, 8, 861-871.	1.4	20

#	ARTICLE	IF	CITATIONS
55	Comparison of left ventricular longitudinal systolic function parameters in the prediction of adverse outcome in heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 1531-1540.	1.4	9
56	Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction. Kardiologia Polska, 2021, 79, 363-370.	0.3	4
57	Sodium-glucose cotransporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. European Journal of Heart Failure, 2021, 23, 826-834.	2.9	60
58	Effect of dapagliflozin on anaemia in DAPA-HF. European Journal of Heart Failure, 2021, 23, 617-628.	2.9	57
59	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2021, 23, 527-540.	2.9	37
60	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. European Heart Journal, 2021, 42, 1254-1269.	1.0	78
61	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 2021, 23, 601-613.	2.9	33
62	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, 2021, 23, 352-380.	2.9	630
63	Oxygenation pattern and compensatory responses to hypoxia and hypercapnia following bilateral carotid body resection in humans. Journal of Physiology, 2021, 599, 2323-2340.	1.3	17
64	Rationale and design of the AMULET study: A new Model of telemedical care in patients with heart failure. ESC Heart Failure, 2021, 8, 2569-2579.	1.4	8
65	Not all fluid overloads are the same: some practical considerations for better decongestion. European Journal of Heart Failure, 2021, 23, 1106-1109.	2.9	5
66	Transvenous Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea: Five-Year Safety and Efficacy Outcomes. Nature and Science of Sleep, 2021, Volume 13, 515-526.	1.4	30
67	Primary Human Cardiomyocytes and Cardiofibroblasts Treated with Sera from Myocarditis Patients Exhibit an Increased Iron Demand and Complex Changes in the Gene Expression. Cells, 2021, 10, 818.	1.8	8
68	Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure, 2021, 27, 387-413.	0.7	362
69	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. JACC: Heart Failure, 2021, 9, 254-264.	1.9	75
70	Iron status, catabolic/anabolic balance, and skeletal muscle performance in men with heart failure with reduced ejection fraction. Cardiology Journal, 2021, 28, 391-401.	0.5	4
71	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 872-881.	2.9	160
72	EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSIDE IN PATIENTS WITH IRON DEFICIENCY FOLLOWING ACUTE HEART FAILURE, ACCORDING TO BASELINE EGFR: A SUBGROUP ANALYSIS OF THE AFFIRM-AHF TRIAL. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	1

#	ARTICLE	IF	CITATIONS
73	Targeting Iron Deficiency in Heart Failure: Existing Evidence and Future Expectations. <i>Circulation: Heart Failure</i> , 2021, 14, e008299.	1.6	5
74	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021, 143, 1962-1972.	1.6	35
75	Spot urine sodium in acute heart failure: differences in prognostic value on admission and discharge. <i>ESC Heart Failure</i> , 2021, 8, 2597-2602.	1.4	17
76	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 499.	3.0	120
77	Low ventilatory responsiveness to transient hypoxia or breath-holding predicts fast marathon performance in healthy middle-aged and older men. <i>Scientific Reports</i> , 2021, 11, 10255.	1.6	1
78	Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising <sc>AFFIRM&AHF</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 1687-1697.	2.9	23
79	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the <sc>VICTORIA</sc> (<sc>Vericiguat</sc> Global Study in) Tj ETQq1 1 0.7849 14 rgB58 Overlock	1.4	14
80	Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 678.	3.0	26
81	Catabolic/Anabolic Imbalance Is Accompanied by Changes of Left Ventricular Steroid Nuclear Receptor Expression in Tachycardia-Induced Systolic Heart Failure in Male Pigs. <i>Journal of Cardiac Failure</i> , 2021, 27, 682-692.	0.7	3
82	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1298-1305.	3.0	12
83	Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. <i>Journal of the American College of Cardiology</i> , 2021, 78, 97-108.	1.2	73
84	Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the <sc>VICTORIA</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1300-1312.	2.9	35
85	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 808-811.	0.7	7
86	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. <i>European Journal of Heart Failure</i> , 2021, 23, 1662-1672.	2.9	36
87	Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. <i>European Journal of Heart Failure</i> , 2021, 23, 1677-1686.	2.9	11
88	Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. <i>Circulation</i> , 2021, 144, 1265-1267.	1.6	5
89	Pol-tako â€” the first, nationwide Polish multicenter analysis of patients with takotsubo syndrome. <i>Kardiologia Polska</i> , 2021, 79, 867-869.	0.3	1
90	The short-term benefit from nurse-led ambulatory care supported by non-invasive haemodynamic assessment in patients after acute heart failure decompensation depends on time since hospital discharge. <i>Kardiologia Polska</i> , 2021, 79, 855-857.	0.3	0

#	ARTICLE	IF	CITATIONS
91	Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary. <i>European Journal of Heart Failure</i> , 2021, 23, 1597-1609.	2.9	20
92	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	2.0	32
93	Impact of mitral regurgitation in patients with worsening heart failure: insights from <sc>BIOSTATâ€CHF</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 1750-1758.	2.9	32
94	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). <i>Circulation</i> , 2021, 144, 1489-1499.	1.6	21
95	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. <i>European Heart Journal</i> , 2021, 42, 3727-3738.	1.0	125
96	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	13.9	2,143
97	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	1.0	5,558
98	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. <i>ESC Heart Failure</i> , 2021, 8, 4409-4424.	1.4	7
99	Intravenous ferric carboxymaltose does not provide benefits in reperfused acute myocardial infarction in the rat with normal iron status. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111893.	2.5	3
100	Role of skeletal muscle perfusion and insulin resistance in the effect of dietary sodium on heart function in overweight. <i>ESC Heart Failure</i> , 2021, 8, 5304-5315.	1.4	4
101	Heart failure in COVID-19: the multicentre, multinational PCHFâ€COVICAV registry. <i>ESC Heart Failure</i> , 2021, 8, 4955-4967.	1.4	26
102	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1337-1348.	1.2	52
103	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. <i>ESC Heart Failure</i> , 2021, 8, 4394-4408.	1.4	5
104	Intravenous iron supplementation: novel anti-remodelling therapy for patients with heart failure?. <i>European Heart Journal</i> , 2021, , .	1.0	6
105	Clinical Outcome Predictions for the Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 949-956.	0.7	8
106	Amended <sc>STRONGâ€HF</sc> study design. <i>European Journal of Heart Failure</i> , 2021, 23, 1981-1982.	2.9	8
107	HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge. <i>ESC Heart Failure</i> , 2021, 8, 4425-4443.	1.4	10
108	Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure. <i>European Heart Journal</i> , 2021, 42, 4468-4477.	1.0	16

#	ARTICLE	IF	CITATIONS
109	Pathophysiology of Advanced Heart Failure. <i>Heart Failure Clinics</i> , 2021, 17, 519-531.	1.0	9
110	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021, 42, 700-710.	1.0	117
111	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021, 42, 3011-3020.	1.0	71
112	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. <i>Diabetes Care</i> , 2021, 44, 586-594.	4.3	50
113	<scp>COVID</scp>â€19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	2.9	32
114	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 890-903.	1.9	7
115	Acute hyperoxia reveals tonic influence of peripheral chemoreceptors on systemic vascular resistance in heart failure patients. <i>Scientific Reports</i> , 2021, 11, 20823.	1.6	7
116	Distinct renin/aldosterone activity profiles correlate with renal function, natriuretic response, decongestive ability and prognosis in acute heart failure. <i>International Journal of Cardiology</i> , 2021, 345, 54-60.	0.8	12
117	OUP accepted manuscript. <i>European Heart Journal</i> , 2021, , .	1.0	1
118	Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure. <i>Biomolecules</i> , 2021, 11, 1701.	1.8	5
119	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008837.	1.6	21
120	Navigating between Scylla and Charybdis: challenges and strategies for implementing guidelineâ€directed medical therapy in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 1999-2007.	2.9	22
121	128â€Clinical impact of changes in mitral regurgitation severity after optimization of medical therapy in heart failure: insights from BIOSTAT-CHF. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
122	Iron deficiency as an emerging therapeutic target in patients stabilized after an episode of acute heart failure. <i>Cardiology Journal</i> , 2021, 28, 962-969.	0.5	1
123	Expression of sex steroid receptors and aromatase in adipose tissue in different body regions in men with coronary artery disease with and without ischemic systolic heart failure. <i>Aging Male</i> , 2020, 23, 141-153.	0.9	9
124	Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. <i>European Journal of Heart Failure</i> , 2020, 22, 70-80.	2.9	28
125	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , 2020, 22, 1147-1155.	2.9	50
126	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 519-527.	2.9	15

#	ARTICLE	IF	CITATIONS
127	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 315-329.	2.9	24
128	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. <i>Circulation</i> , 2020, 141, 100-111.	1.6	145
129	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 141, 90-99.	1.6	244
130	Clinical value of pre-discharge bioadrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. <i>European Journal of Heart Failure</i> , 2020, 22, 683-691.	2.9	33
131	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 196-213.	2.9	131
132	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. <i>JACC: Heart Failure</i> , 2020, 8, 931-939.	1.9	88
133	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1984-1986.	2.9	66
134	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€HF</scp> baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.	2.9	47
135	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1512.	3.8	170
136	Myocardial iron content in non-ischaemic cardiomyopathy: how much is known?. <i>European Journal of Heart Failure</i> , 2020, 22, 2047-2048.	2.9	1
137	Cause of Death in Patients With Acute Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 999-1008.	1.9	12
138	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet, The</i> , 2020, 396, 1895-1904.	6.3	425
139	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPERORâ€Preserved trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2383-2392.	2.9	93
140	Elevated plasma endothelin-1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure. <i>ESC Heart Failure</i> , 2020, 7, 3536-3544.	1.4	12
141	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). <i>European Journal of Heart Failure</i> , 2020, 22, 2272-2289.	2.9	92
142	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 142, 1623-1632.	1.6	51
143	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <i>European Heart Journal</i> , 2020, 41, 3787-3797.	1.0	101
144	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	13.9	2,821

#	ARTICLE	IF	CITATIONS
145	Distinct clinical phenotypes of congestion in acute heart failure: characteristics, treatment response, and outcomes. <i>ESC Heart Failure</i> , 2020, 7, 3830-3840.	1.4	10
146	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020, 41, 3402-3418.	1.0	90
147	Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e007879.	1.6	14
148	10-year trends in hospitalization rates due to heart failure and related in-hospital mortality in Poland (2010-2019). <i>ESC Heart Failure</i> , 2020, 7, 3365-3373.	1.4	5
149	The Effects of a Marathon Effort on Psychomotor Performance and Catecholamine Concentration in Runners over 50 Years of Age. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2067.	1.3	7
150	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. <i>European Heart Journal</i> , 2020, 41, 1810-1817.	1.0	381
151	Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 941-956.	2.9	95
152	Looking at the heart failure through the prism of liver dysfunction. <i>European Journal of Heart Failure</i> , 2020, 22, 1672-1674.	2.9	5
153	Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1247-1258.	2.9	29
154	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	1.0	65
155	Re: Pacing, takotsubo syndrome, and transient rise of pacing threshold: What is the mechanism?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 772-773.	0.5	0
156	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1353.	3.8	340
157	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020, 382, 1883-1893.	13.9	753
158	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. <i>European Heart Journal</i> , 2020, 41, 2379-2392.	1.0	151
159	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 391-412.	2.9	193
160	Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-HF2 trial. <i>European Journal of Heart Failure</i> , 2020, 22, 726-738.	2.9	21
161	Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan. <i>JACC: Heart Failure</i> , 2020, 8, 811-818.	1.9	87
162	Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1495-1503.	2.9	100

#	ARTICLE	IF	CITATIONS
163	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. <i>Clinical Research in Cardiology</i> , 2020, 109, 967-977.	1.5	7
164	Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 999-1005.	2.9	71
165	Mega-trials in heart failure: effects of dilution in examination of new therapies. <i>European Journal of Heart Failure</i> , 2020, 22, 1698-1707.	2.9	11
166	Frailty and cognitive impairment are predictive of takotsubo syndrome following pacemaker implantation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 730-736.	0.5	2
167	Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2020, 109, 1048-1059.	1.5	20
168	Cardiac emergencies during the coronavirus disease 2019 pandemic in the light of the current evidence. <i>Kardiologia Polska</i> , 2020, 78, 818-824.	0.3	7
169	On the search for the right definition of heart failure with preserved ejection fraction. <i>Cardiology Journal</i> , 2020, 27, 449-468.	0.5	13
170	Chloroquine and hydroxychloroquine for the prevention and therapy of coronavirus disease 2019: new hopes and old cardiovascular concerns. <i>Kardiologia Polska</i> , 2020, 78, 811-817.	0.3	0
171	Medical emergency team interventions in patients with ST-segment elevation myocardial infarction in Poland in 2018. <i>Kardiologia Polska</i> , 2020, 78, 292-299.	0.3	3
172	Effects of running a marathon on irisin concentration in men aged over 50. <i>Journal of Physiological Sciences</i> , 2019, 69, 79-84.	0.9	7
173	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	1.0	4,537
174	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 4-90.	0.6	402
175	Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. <i>European Journal of Heart Failure</i> , 2019, 21, 1459-1467.	2.9	34
176	The Relationship between LVEF and Cardiovascular Outcomes Following Hospitalization for Heart failure: Insights from the RELAX-AHF-2 Trial. <i>Journal of Cardiac Failure</i> , 2019, 25, S55.	0.7	0
177	Effects of Serelaxin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , 2019, 381, 716-726.	13.9	174
178	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	2.9	155
179	Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 866-874.	0.7	16
180	The Dapagliflozin And Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. <i>European Journal of Heart Failure</i> , 2019, 21, 1402-1411.	2.9	159

#	ARTICLE	IF	CITATIONS
181	Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. ESC Heart Failure, 2019, 6, 1188-1198.	1.4	22
182	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. European Journal of Heart Failure, 2019, 21, 1561-1570.	2.9	9
183	Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure. European Journal of Heart Failure, 2019, 21, 1299-1305.	2.9	144
184	Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. JACC: Heart Failure, 2019, 7, 970-979.	1.9	26
185	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2019, 40, 3297-3317.	1.0	944
186	Association between Left Ventricular Ejection Fraction and Worsening Renal Function in Acute Heart Failure: Insights from the RELAX-AHF-2 Trial. Journal of Cardiac Failure, 2019, 25, S51.	0.7	0
187	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019, 381, 1995-2008.	13.9	4,108
188	Long-term efficacy and safety of phrenic nerve stimulation for the treatment of central sleep apnea. Sleep, 2019, 42, .	0.6	40
189	Hypoxic tachycardia is not a result of increased respiratory activity in healthy subjects. Experimental Physiology, 2019, 104, 476-489.	0.9	11
190	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 1169-1186.	2.9	490
191	Controlled decongestion by Rerieve therapy in acute heart failure: results of the TARGET-1 and TARGET-2 studies. European Journal of Heart Failure, 2019, 21, 1079-1087.	2.9	27
192	Trimetazidine in cardiovascular medicine. International Journal of Cardiology, 2019, 293, 39-44.	0.8	59
193	Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure. European Journal of Heart Failure, 2019, 21, 932-942.	2.9	40
194	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2019, 21, 827-843.	2.9	223
195	Rationale and Design of the VITALITY-HFpEF Trial. Circulation: Heart Failure, 2019, 12, e005998.	1.6	33
196	Acute heart failure congestion and perfusion status: impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. European Journal of Heart Failure, 2019, 21, 1338-1352.	2.9	170
197	Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy. ESC Heart Failure, 2019, 6, 621-628.	1.4	19
198	The clinical significance of interleukin-6 in heart failure: results from the BIostat-HF study. European Journal of Heart Failure, 2019, 21, 965-973.	2.9	172

#	ARTICLE	IF	CITATIONS
199	Effectiveness of screening for atrial fibrillation and its determinants. A meta-analysis. PLoS ONE, 2019, 14, e0213198.	1.1	38
200	A trial to evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). European Journal of Heart Failure, 2019, 21, 665-675.	2.9	264
201	Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial. ESC Heart Failure, 2019, 6, 297-307.	1.4	7
202	Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 321-332.	1.9	33
203	Seat belts-related behaviors in car drivers with cardiac implantable electronic devices. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 400-406.	0.5	2
204	Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. European Journal of Heart Failure, 2019, 21, 921-929.	2.9	86
205	Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. European Journal of Heart Failure, 2019, 21, 624-633.	2.9	63
206	Pulse pressure and prognosis in patients with heart failure with reduced ejection fraction. European Journal of Clinical Investigation, 2019, 49, e13092.	1.7	1
207	The year in cardiology 2018: heart failure. European Heart Journal, 2019, 40, 651-661.	1.0	32
208	Heart rate and blood pressure monitoring in heart failure. European Heart Journal Supplements, 2019, 21, M13-M16.	0.0	9
209	Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. European Journal of Heart Failure, 2019, 21, 1651-1658.	2.9	42
210	Drug therapy in elderly heart failure patients. European Heart Journal Supplements, 2019, 21, L8-L11.	0.0	5
211	Cognitive Decline Over Time in Patients With Systolic Heart Failure. JACC: Heart Failure, 2019, 7, 1042-1053.	1.9	26
212	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22	2.9	65
213	Monitoring of iron status in patients with heart failure. European Heart Journal Supplements, 2019, 21, M32-M35.	0.0	10
214	Assessment of baroreflex sensitivity has no prognostic value in contemporary, optimally managed patients with mild-to-moderate heart failure with reduced ejection fraction: a retrospective analysis of 5-year survival. European Journal of Heart Failure, 2019, 21, 50-58.	2.9	11
215	Multi-organ dysfunction/injury on admission identifies acute heart failure patients at high risk of poor outcome. European Journal of Heart Failure, 2019, 21, 744-750.	2.9	32
216	Iron Deficiency in Heart Failure. JACC: Heart Failure, 2019, 7, 36-46.	1.9	195

#	ARTICLE	IF	CITATIONS
217	Patterns of dyspnoea onset in patients with acute heart failure: clinical and prognostic implications. ESC Heart Failure, 2019, 6, 16-26.	1.4	12
218	Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. Clinical Research in Cardiology, 2019, 108, 797-805.	1.5	10
219	Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF. European Journal of Heart Failure, 2019, 21, 877-886.	2.9	68
220	Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Failure, 2019, 6, 62-69.	1.4	45
221	Cardiovascular stress biomarker assessment of middle-aged non-athlete marathon runners. European Journal of Preventive Cardiology, 2019, 26, 318-327.	0.8	21
222	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644.	1.0	123
223	Structural and functional abnormalities in iron-depleted heart. Heart Failure Reviews, 2019, 24, 269-277.	1.7	32
224	Enzyme replacement therapy in Fabry disease in Poland – position statement. Polish Archives of Internal Medicine, 2019, 130, 91-97.	0.3	9
225	Comprehensive Heart Failure Care pilot study: starting point and expected developments. Kardiologia Polska, 2019, 77, 994-999.	0.3	5
226	Iron deficiency in heart failure: a 2020 update. Kardiologia Polska, 2019, 77, 1134-1139.	0.3	3
227	Clinical, respiratory, haemodynamic, and metabolic determinants of lactate in heart failure. Kardiologia Polska, 2019, 77, 47-52.	0.3	20
228	Elevated lactate in acute heart failure patients with intracellular iron deficiency as identifier of poor outcome. Kardiologia Polska, 2019, 77, 347-354.	0.3	18
229	Persistent hyperlactataemia is related to high rates of in-hospital adverse events and poor outcome in acute heart failure. Kardiologia Polska, 2019, 77, 355-362.	0.3	10
230	Relationship between the CHA2DS2-VASc score and atrial fibrillation in patients hospitalised due to heart failure. Kardiologia Polska, 2019, 77, 380-385.	0.3	2
231	Phrenic nerve stimulation in patients with central sleep apnea: a single-center experience from pilot and pivotal trials evaluating the remedÅ™ System. Kardiologia Polska, 2019, 77, 553-560.	0.3	2
232	Recommendations on the use of innovative medical technologies in cardiology and cardiac surgery and solutions leading to increased availability for Polish patients. Cardiology Journal, 2019, 26, 114-129.	0.5	3
233	True worsening renal function identifies patients with acute heart failure with an ominous outcome. Polish Archives of Internal Medicine, 2019, 129, 357-360.	0.3	7
234	Prognostic importance of serum troponin concentration in patients with an implanted cardioverter-defibrillator admitted to the emergency department due to electric shock. Kardiologia Polska, 2019, 77, 618-623.	0.3	2

#	ARTICLE	IF	CITATIONS
235	Predictors of inappropriate shocks from implantable cardioverter-defibrillators. <i>Wiadomości Lekarskie</i> , 2019, 72, 1243-1246.	0.1	0
236	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patientsâ€”who is doing what to whom and how?. <i>European Journal of Heart Failure</i> , 2018, 20, 1039-1051.	2.9	107
237	Acute heart failure: lessons learned, roads ahead. <i>European Journal of Heart Failure</i> , 2018, 20, 842-850.	2.9	17
238	Iron limitation promotes the atrophy of skeletal myocytes, whereas iron supplementation prevents this process in the hypoxic conditions. <i>International Journal of Molecular Medicine</i> , 2018, 41, 2678-2686.	1.8	12
239	Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea. <i>American Journal of Cardiology</i> , 2018, 121, 1400-1408.	0.7	30
240	Depleted iron stores are associated with inspiratory muscle weakness independently of skeletal muscle mass in men with systolic chronic heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 547-556.	2.9	39
241	Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion. <i>European Journal of Heart Failure</i> , 2018, 20, 1011-1018.	2.9	85
242	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 386-398.	1.2	35
243	Proportional pulse pressure relates to cardiac index in stabilized acute heart failure patients. <i>Clinical and Experimental Hypertension</i> , 2018, 40, 637-643.	0.5	4
244	Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 260-267.	2.9	30
245	Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. <i>International Journal of Cardiology</i> , 2018, 253, 91-96.	0.8	2
246	Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSSTATâ€”CHF. <i>European Journal of Heart Failure</i> , 2018, 20, 923-930.	2.9	57
247	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. <i>International Journal of Cardiology</i> , 2018, 253, 84-90.	0.8	55
248	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 180-188.	1.4	113
249	Temporal trends in secondary prevention in myocardial infarction patients discharged with left ventricular systolic dysfunction in Poland. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 960-969.	0.8	20
250	Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. <i>International Journal of Cardiology</i> , 2018, 258, 185-191.	0.8	157
251	2018 ESC Guidelines for the diagnosis and management of syncope. <i>European Heart Journal</i> , 2018, 39, 1883-1948.	1.0	1,200
252	Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 125-133.	2.9	317

#	ARTICLE	IF	CITATIONS
253	Iron deficiency and red cell indices in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 114-122.	2.9	54
254	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). <i>European Heart Journal</i> , 2018, 39, 763-816.	1.0	2,305
255	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2018, 39, 119-177.	1.0	7,100
256	Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 715-722.	2.9	41
257	Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 8-17.	1.9	140
258	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator. <i>JACC: Heart Failure</i> , 2018, 6, 96-104.	1.9	141
259	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. <i>Clinical Research in Cardiology</i> , 2018, 107, 170-181.	1.5	27
260	Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 3-15.	2.9	157
261	Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. <i>Heart</i> , 2018, 104, 606-613.	1.2	16
262	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. <i>Clinical Proteomics</i> , 2018, 15, 35.	1.1	6
263	Expression of $\alpha 7$ Nicotinic ACh Receptors in Blood Mononuclear Cells: Correlation with Impaired Baroreflex Sensitivity in Patients with Heart Failure. <i>Neurophysiology</i> , 2018, 50, 249-253.	0.2	0
264	Novel endotypes in heart failure: effects on guideline-directed medical therapy. <i>European Heart Journal</i> , 2018, 39, 4269-4276.	1.0	44
265	Phrenic Nerve Stimulation for Central Sleep Apnea is Effective and Safe in the Presence of Concomitant Cardiac Devices. <i>Journal of Cardiac Failure</i> , 2018, 24, S17-S18.	0.7	1
266	Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1746-1754.	2.9	64
267	Effect of Implantable Cardioverter-Defibrillators by Etiology of Heart Failure: A Propensity-Matched Mortality Analysis of the WARCEF Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, S75.	0.7	0
268	Iron Depletion Affects Genes Encoding Mitochondrial Electron Transport Chain and Genes of Non-Oxidative Metabolism, Pyruvate Kinase and Lactate Dehydrogenase, in Primary Human Cardiac Myocytes Cultured upon Mechanical Stretch. <i>Cells</i> , 2018, 7, 175.	1.8	15
269	Iron deficiency as energetic insult to skeletal muscle in chronic diseases. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 802-815.	2.9	71
270	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018, 271, 132-139.	0.8	140

#	ARTICLE	IF	CITATIONS
271	Evaluation of Skeletal Muscle Function and Effects of Early Rehabilitation during Acute Heart Failure: Rationale and Study Design. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	11
272	Waist-to-hip ratio and mortality in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1269-1277.	2.9	85
273	Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta β -adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta β -left ventricular hypertrophy (Beta β -LVH). <i>ESC Heart Failure</i> , 2018, 5, 830-841.	1.4	29
274	Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment. <i>ESC Heart Failure</i> , 2018, 5, 800-808.	1.4	25
275	Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion. <i>Circulation: Heart Failure</i> , 2018, 11, e004644.	1.6	58
276	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>European Heart Journal</i> , 2018, 39, 3165-3241.	1.0	1,396
277	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1081-1090.	1.2	199
278	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018, 39, 3867-3875.	1.0	47
279	Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). <i>American Journal of Cardiology</i> , 2018, 122, 821-827.	0.7	3
280	Validation of transurethral intra-abdominal pressure measurement in acute heart failure. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 403-405.	0.3	7
281	Impact of digoxin on risk of death in heart failure patients treated with b-blockers. Results from Polish part of ESC Heart Failure Long-Term Registry. <i>Kardiologia Polska</i> , 2018, 76, 1064-1072.	0.3	4
282	The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure. <i>Kardiologia Polska</i> , 2018, 76, 1336-1343.	0.3	14
283	Human carotid bodies as a therapeutic target: new insights from a clinician's perspective. <i>Kardiologia Polska</i> , 2018, 76, 1426-1433.	0.3	7
284	Clinical profile and management of outpatients with non-ischemic and non-hypertensive systolic heart failure: Analysis of the Polish DATA-HELP registry. <i>Cardiology Journal</i> , 2018, 25, 512-520.	0.5	2
285	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	11
286	Elevated troponin I level assessed by a new high-sensitive assay and the risk of poor outcomes in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2017, 230, 646-652.	0.8	13
287	Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 760-767.	2.9	52
288	A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1001-1010.	2.9	81

#	ARTICLE	IF	CITATIONS
289	Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. <i>Clinical Research in Cardiology</i> , 2017, 106, 444-456.	1.5	8
290	Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (<scp>PPCM</scp>). <i>European Journal of Heart Failure</i> , 2017, 19, 1131-1141.	2.9	163
291	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. <i>Heart</i> , 2017, 103, 407-413.	1.2	74
292	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 627-634.	2.9	183
293	Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 728-738.	2.9	34
294	Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 517-534.	1.3	4
295	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2017, 376, 1956-1964.	13.9	257
296	Resting Heart Rate and Ischemic Stroke in Patients with Heart Failure. <i>Cerebrovascular Diseases</i> , 2017, 44, 43-50.	0.8	5
297	Iron Deficiency Treatment in Patients with Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2017, 243, 561-576.	0.9	7
298	Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 243, 360-366.	0.8	42
299	Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. <i>European Journal of Heart Failure</i> , 2017, 19, 800-809.	2.9	104
300	Effect of ivabradine in patients with heart failure with preserved ejection fraction: the <scp>EDIFY</scp> randomized placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1495-1503.	2.9	154
301	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , 2017, 38, 2364-2373.	1.0	102
302	Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the <scp>QUALIFY</scp> international registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1414-1423.	2.9	183
303	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 507-517.	1.9	78
304	Patient-reported outcomes in the <scp>SOLuble</scp> guanylate Cyclase <scp>stimuloR</scp> in <scp>heArT failurE patientS</scp> with <scp>PRESERVED</scp> ejection fraction (<scp>SOCRATESâ€PRESERVED</scp>) study. <i>European Journal of Heart Failure</i> , 2017, 19, 782-791.	2.9	84
305	Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017, 190, 113-122.	1.2	10
306	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimuloR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. <i>European Heart Journal</i> , 2017, 38, 1119-1127.	1.0	285

#	ARTICLE	IF	CITATIONS
307	Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. <i>European Heart Journal</i> , 2017, 38, 1883-1890.	1.0	299
308	Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017, 187, 62-69.	1.2	9
309	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , 2017, 19, 718-727.	2.9	17
310	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
311	Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 183-201.	1.0	35
312	Non-invasive approach for the assessment of sympathetic baroreflex function: A feasibility study. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2017, 203, 108-112.	1.4	1
313	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 616-664.	0.6	510
314	In Heart Failure Patients with CSA, Stimulation of the Phrenic Nerve Improves Sleep and Quality of Life. <i>Journal of Cardiac Failure</i> , 2017, 23, S15.	0.7	0
315	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2017, 19, 1361-1378.	2.9	115
316	Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1690-1697.	2.9	34
317	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2128-2136.	1.2	43
318	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Heart Journal</i> , 2017, 38, 2739-2791.	1.0	5,142
319	What have we learned about heart failure with mid-range ejection fraction one year after its introduction?. <i>European Journal of Heart Failure</i> , 2017, 19, 1569-1573.	2.9	67
320	The potential role and rationale for treatment of heart failure with sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	2.9	139
321	Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients. <i>JACC: Heart Failure</i> , 2017, 5, 603-610.	1.9	2
322	Transvenous Phrenic Nerve Stimulation Effectiveness is Sustained at 18 Months: Data From the Remede System Pivotal Trial. <i>Chest</i> , 2017, 152, A734.	0.4	0
323	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 1310-1320.	2.9	53
324	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation</i> , 2017, 136, 1374-1383.	1.6	289

#	ARTICLE	IF	CITATIONS
325	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 281-293.	1.3	8
326	Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. <i>Clinical Research in Cardiology</i> , 2017, 106, 280-292.	1.5	17
327	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Journal of Heart Failure</i> , 2017, 19, 9-42.	2.9	920
328	Carotid body resection for sympathetic modulation in systolic heart failure: results from firstâ€inâ€man study. <i>European Journal of Heart Failure</i> , 2017, 19, 391-400.	2.9	97
329	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2017, 23, 231-239.	0.7	30
330	Central Chemoreceptor Sensitivity Is Not Enhanced in Contemporary Patients With Chronic Systolic Heart Failure Receiving Optimal Treatment. <i>Journal of Cardiac Failure</i> , 2017, 23, 83-87.	0.7	3
331	Rationale for and design of the <scp>TRUEâ€AHF</scp> trial: the effects of ularitide on the shortâ€term clinical course and longâ€term mortality of patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 673-681.	2.9	31
332	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	39
333	Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 440-451.	1.0	38
334	The story of carotid body resection for HF. <i>European Heart Journal</i> , 2017, 38, 3481-3482.	1.0	3
335	Muscle Ergoreflex Activity and Autonomic Balance Assessed in the Vertical and Horizontal Body Positions in Young Healthy Men. <i>Neurophysiology</i> , 2017, 49, 288-294.	0.2	0
336	Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1470.	1.8	17
337	253Effect of i.v. ferric carboxymaltose iron therapy on symptoms and functional status in iron-deficient patients with HFrEF and renal dysfunction: An individual patient data meta-analysis. <i>European Heart Journal</i> , 2017, 38, .	1.0	0
338	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from <scp>BIOSTATâ€CHF</scp>. <i>European Journal of Heart Failure</i> , 2017, 19, 1284-1293.	2.9	79
339	Adherence to systolic heart failure guidelines in ambulatory care in Poland â€“ data from the international QUALIFY survey. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 657-665.	0.3	8
340	Both iron excess and iron depletion impair viability of rat H9C2 cardiomyocytes and L6G8C5 myocytes. <i>Kardiologia Polska</i> , 2017, 75, 267-275.	0.3	20
341	Acute heart failure in patients admitted to the emergency department with acute myocardial infarction. <i>Kardiologia Polska</i> , 2017, 75, 306-315.	0.3	4
342	Hospitalisation length and prognosis in heart failure patients. <i>Kardiologia Polska</i> , 2017, 75, 323-331.	0.3	10

#	ARTICLE	IF	CITATIONS
343	InterAtrial Shunt Device (IASD®) implantation – a novel treatment method for heart failure with preserved ejection fraction. <i>Kardiologia Polska</i> , 2017, 75, 736-741.	0.3	2
344	Attitude towards knowledge of the disease and psychological characteristics of patients with systolic heart failure. <i>Health Psychology Report</i> , 2017, 1, 30-40.	0.5	0
345	Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society. <i>Kardiologia Polska</i> , 2017, 75, 286-293.	0.3	0
346	Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society. <i>Kardiologia Polska</i> , 2017, 75, 33-41.	0.3	0
347	Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure. <i>Stroke</i> , 2016, 47, 2031-2037.	1.0	44
348	Signature of circulating microRNAs in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 414-423.	2.9	162
349	Optimizing clinical use of biomarkers in high-risk acute heart failure patients. <i>European Journal of Heart Failure</i> , 2016, 18, 269-280.	2.9	69
350	The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications. <i>European Journal of Heart Failure</i> , 2016, 18, 762-773.	2.9	102
351	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , 2016, 18, 672-683.	2.9	21
352	Telerehabilitation in heart failure patients: The evidence and the pitfalls. <i>International Journal of Cardiology</i> , 2016, 220, 408-413.	0.8	73
353	Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. <i>European Journal of Heart Failure</i> , 2016, 18, 786-795.	2.9	270
354	Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. <i>European Journal of Heart Failure</i> , 2016, 18, 830-839.	2.9	70
355	One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	113
356	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet</i> , 2016, 388, 2895-2903.	6.3	229
357	Iron Deficiency in Heart Failure. , 2016, , 535-547.		0
358	Contemporary Pharmacological Treatment of Heart Failure. , 2016, , 207-227.		0
359	Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes. <i>JACC: Heart Failure</i> , 2016, 4, 591-599.	1.9	49
360	The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2016, 219, 84-91.	0.8	9

#	ARTICLE	IF	CITATIONS
361	Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia. <i>American Journal of Cardiology</i> , 2016, 117, 1482-1487.	0.7	12
362	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2016, 37, 2129-2200.	1.0	13,008
363	Increased body fat is associated with potentiation of blood pressure response to hypoxia in healthy men: relations with insulin and leptin. <i>Clinical Autonomic Research</i> , 2016, 26, 107-116.	1.4	10
364	Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure – Post-hoc analysis of the PROTECT trial. <i>International Journal of Cardiology</i> , 2016, 223, 967-975.	0.8	6
365	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, e1-e88.	0.6	754
366	Impaired hepato-renal function defined by the MELD XI score as prognosticator in acute heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 1518-1521.	2.9	53
367	Could gonadal and adrenal androgen deficiencies contribute to the depressive symptoms in men with systolic heart failure?. <i>Aging Male</i> , 2016, 19, 221-230.	0.9	14
368	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. <i>International Journal of Cardiology</i> , 2016, 224, 231-239.	0.8	53
369	Acute heart failure in the young: Clinical characteristics and biomarker profiles. <i>International Journal of Cardiology</i> , 2016, 221, 1067-1072.	0.8	11
370	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	80
371	Transvenous stimulation of the phrenic nerve for the treatment of central sleep apnoea: 12 months' experience with the <i>remed^Å</i> System. <i>European Journal of Heart Failure</i> , 2016, 18, 1386-1393.	2.9	43
372	What does the lay public know about heart failure? Findings from the Heart Failure Awareness Day Initiative. <i>European Journal of Heart Failure</i> , 2016, 18, 66-70.	2.9	24
373	Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. <i>European Journal of Heart Failure</i> , 2016, 18, 641-649.	2.9	32
374	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 891-975.	2.9	5,272
375	<sc>CHA ₂ DS ₂ -VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. <i>European Journal of Heart Failure</i> , 2016, 18, 1261-1266.	2.9	25
376	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016, 37, 2893-2962.	1.0	5,689
377	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016, 18, 1609-1678.	0.7	3,523
378	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Heart Journal</i> , 2016, 37, 2768-2801.	1.0	1,996

#	ARTICLE	IF	CITATIONS
379	Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. <i>Lancet</i> , The, 2016, 388, 974-982.	6.3	142
380	Iron deficiency in heart failure: Impact on response to cardiac resynchronization therapy. <i>International Journal of Cardiology</i> , 2016, 222, 133-134.	0.8	8
381	Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure – Subanalysis of the WARCEF Trial. <i>Circulation Journal</i> , 2016, 80, 619-626.	0.7	11
382	2016 ESC and ACC/AHA/HFSA heart failure guideline update – what is new and why is it important?. <i>Nature Reviews Cardiology</i> , 2016, 13, 623-628.	6.1	38
383	Effects of selective carotid body stimulation with adenosine in conscious humans. <i>Journal of Physiology</i> , 2016, 594, 6225-6240.	1.3	28
384	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. <i>European Heart Journal</i> , 2016, 37, 2105-2114.	1.0	274
385	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	51
386	What's new in the European Society of Cardiology 2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure?. <i>European Heart Journal</i> , 2016, 37, 3121-3122.	1.0	6
387	Influence of the availability of iron during hypoxia on the genes associated with apoptotic activity and local iron metabolism in rat H9C2 cardiomyocytes and L6G8C5 skeletal myocytes. <i>Molecular Medicine Reports</i> , 2016, 14, 3969-3977.	1.1	16
388	A systems Biology Study to Tailored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIostat-CHF. <i>European Journal of Heart Failure</i> , 2016, 18, 716-726.	2.9	149
389	Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. <i>European Journal of Heart Failure</i> , 2016, 18, 1041-1050.	2.9	49
390	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	35
391	Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. <i>European Journal of Heart Failure</i> , 2016, 18, 514-522.	2.9	193
392	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2016, 23, NP1-NP96.	0.8	683
393	Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. <i>Gene Therapy</i> , 2016, 23, 313-319.	2.3	79
394	Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. <i>International Journal of Cardiology</i> , 2016, 204, 164-171.	0.8	34
395	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1444-1455.	1.2	191
396	Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2016, 105, 727-737.	1.5	16

#	ARTICLE	IF	CITATIONS
397	Could the two-minute step test be an alternative to the six-minute walk test for patients with systolic heart failure?. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1307-1313.	0.8	37
398	Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. <i>Lancet</i> , The, 2016, 387, 1178-1186.	6.3	373
399	Relationship between central sleep apnea and Cheyne-Stokes Respiration. <i>International Journal of Cardiology</i> , 2016, 206, S8-S12.	0.8	12
400	The first prognostic model for stroke and death in patients with systolic heart failure. <i>Journal of Cardiology</i> , 2016, 68, 100-103.	0.8	13
401	The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure. <i>International Journal of Cardiology</i> , 2016, 205, 6-12.	0.8	104
402	Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 909-915.	0.8	67
403	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 564-569.	0.8	35
404	A combined clinical and biomarker approach to predict diuretic response in acute heart failure. <i>Clinical Research in Cardiology</i> , 2016, 105, 145-153.	1.5	32
405	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>European Heart Journal</i> , 2016, 37, 67-119.	1.0	5,074
406	Nordic Walking May Safely Increase the Intensity of Exercise Training in Healthy Subjects and in Patients with Chronic Heart Failure. <i>Advances in Clinical and Experimental Medicine</i> , 2016, 25, 145-149.	0.6	4
407	Prediction of Post-Discharge Outcomes for Patients Hospitalized with Heart Failure: Results from PROTECT. <i>Journal of Cardiac Failure</i> , 2015, 21, S64.	0.7	0
408	<sc>ExtraHF</sc> survey: the first European survey on implementation of exercise training in heart failure patients. <i>European Journal of Heart Failure</i> , 2015, 17, 631-638.	2.9	69
409	Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. <i>European Journal of Heart Failure</i> , 2015, 17, 544-558.	2.9	315
410	Maintenance of serum potassium with sodium zirconium cyclosilicate (<sc>ZS</sc>®) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1050-1056.	2.9	143
411	Higher serum phosphorus is associated with catabolic/anabolic imbalance in heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015, 6, 325-334.	2.9	15
412	Central Sleep Apnea in Heart Failure Worsens Throughout the Night. <i>Chest</i> , 2015, 148, 1047A.	0.4	1
413	Growth differentiation factor 15 (<sc>GDF</sc>®15) in patients admitted for acute heart failure: results from the <sc>RELAX&AHF</sc> study. <i>European Journal of Heart Failure</i> , 2015, 17, 1133-1143.	2.9	86
414	Sex differences in porcine left ventricular myocardial remodeling due to right ventricular pacing. <i>Biology of Sex Differences</i> , 2015, 6, 32.	1.8	4

#	ARTICLE	IF	CITATIONS
415	Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the <scp>RELAXÁAHF</scp> study. European Journal of Heart Failure, 2015, 17, 1262-1270.	2.9	110
416	Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. European Journal of Heart Failure, 2015, 17, 697-706.	2.9	24
417	InÁhospital worsening heart failure. European Journal of Heart Failure, 2015, 17, 1104-1113.	2.9	60
418	Anaemia (and iron deficiency?) in aortic stenosisÁa bystander or a potential therapeutic target?. European Journal of Heart Failure, 2015, 17, 994-996.	2.9	3
419	Clinical research Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot) Á Polish population. Archives of Medical Science, 2015, 4, 743-750.	0.4	8
420	Iohexol clearance is superior to creatinine-based renal function estimating equations in detecting short-term renal function decline in chronic heart failure. Croatian Medical Journal, 2015, 56, 531-541.	0.2	5
421	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine, 2015, 372, 2387-2397.	13.9	3,337
422	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine Á short version. European Heart Journal, 2015, 36, 1958-1966.	1.0	105
423	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal, 2015, 169, 631-638.e7.	1.2	88
424	Psychological aspects of heart failure Á beyond depression, anxiety and quality of life. Health Psychology Report, 2015, 3, 99-114.	0.5	5
425	Design of the remedÁ System Pivotal Trial: A Prospective, Randomized Study in the Use of Respiratory Rhythm Management to Treat Central Sleep Apnea. Journal of Cardiac Failure, 2015, 21, 892-902.	0.7	46
426	Mechanisms and Clinical Consequences ofÁUntreated Central Sleep Apnea in HeartÁFailure. Journal of the American College of Cardiology, 2015, 65, 72-84.	1.2	120
427	European Cardiac Resynchronization Therapy Survey II: rationale and design. Europace, 2015, 17, 137-141.	0.7	22
428	Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the <scp>PROTECT</scp> trial. European Journal of Heart Failure, 2015, 17, 109-118.	2.9	48
429	A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain. Revista Espanola De Cardiologia (English Ed), 2015, 68, 846-851.	0.4	15
430	Heart Failure Therapeutics on theÁBasisÁofÁBiased Ligand of theÁAngiotensin-2 TypeÁ1ÁReceptor. JACC: Heart Failure, 2015, 3, 193-201.	1.9	68
431	Patogenia y presentaciÁn clÁnica de la insuficiencia cardiaca aguda. Revista Espanola De Cardiologia, 2015, 68, 331-337.	0.6	38
432	Late Cardiac Tamponade as a Result of Parietal Pericardium Erosion. Annals of Thoracic Surgery, 2015, 100, 715-717.	0.7	0

#	ARTICLE	IF	CITATIONS
433	Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. <i>American Journal of Cardiology</i> , 2015, 116, 904-912.	0.7	7
434	Quality of Anticoagulation Control in Preventing Adverse Events in Patients With Heart Failure in Sinus Rhythm. <i>Circulation: Heart Failure</i> , 2015, 8, 504-509.	1.6	21
435	Iron deficiency and cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2015, 12, 659-669.	6.1	220
436	The impact of intravenous ferric carboxymaltose on renal function: an analysis of the <sc>FAIRâ€HF</sc> study. <i>European Journal of Heart Failure</i> , 2015, 17, 329-339.	2.9	92
437	Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Studyâ€Heart Failure (ARTSâ€HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. <i>European Journal of Heart Failure</i> , 2015, 17, 224-232.	2.9	74
438	The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction. <i>European Heart Journal</i> , 2015, 36, 1974-1982.	1.0	193
439	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. <i>New England Journal of Medicine</i> , 2015, 372, 1791-1800.	13.9	1,585
440	Worsening Heart Failure Following Admission for Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 395-403.	1.9	44
441	Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. <i>European Heart Journal</i> , 2015, 36, 715-723.	1.0	69
442	Pathogenesis and Clinical Presentation of Acute Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 331-337.	0.4	16
443	2015 ESC Guidelines for the diagnosis and management of pericardial diseases. <i>European Heart Journal</i> , 2015, 36, 2921-2964.	1.0	1,768
444	Exercise programs for LVAD supported patients: A snapshot from the ESC affiliated countries. <i>International Journal of Cardiology</i> , 2015, 201, 215-219.	0.8	32
445	Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea. <i>JACC: Heart Failure</i> , 2015, 3, 360-369.	1.9	114
446	CUPID 2: A Phase 2b Trial Investigating the Efficacy and Safety of the Intracoronary Administration of AAV1/SERCA2a in Patients with Advanced Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 939-940.	0.7	5
447	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2251.	3.8	288
448	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. <i>European Heart Journal</i> , 2015, 36, 657-668.	1.0	902
449	Bone marrow iron depletion is common in patients with coronary artery disease. <i>International Journal of Cardiology</i> , 2015, 182, 517-522.	0.8	38
450	Vitamin B12and folate deficiency in chronic heart failure. <i>Heart</i> , 2015, 101, 302-310.	1.2	26

#	ARTICLE	IF	CITATIONS
451	Abnormal serum calcium levels are associated with clinical response to maximization of heart failure therapy. Polish Archives of Internal Medicine, 2015, 125, 54-64.	0.3	3
452	Cardioversion differences among first detected episode, paroxysmal, and persistent atrial fibrillation patients in the RHYTHM AF registry in Poland. Cardiology Journal, 2015, 22, 453-458.	0.5	4
453	Sexual dimorphism in socioeconomic differences regarding the risk factors, symptomatology and management of patients with stable coronary artery disease in Poland. Cardiology Journal, 2015, 22, 487-494.	0.5	3
454	Could an analysis of mean corpuscular volume help to improve risk stratification in non-anemic patients with acute myocardial infarction?. Cardiology Journal, 2015, 22, 421-427.	0.5	12
455	Atrial fibrillation in outpatients with stable coronary artery disease : results from the multicenter RECENT study. Polish Archives of Internal Medicine, 2015, 125, 162-171.	0.3	8
456	Cognitive Function in Ambulatory Patients with Systolic Heart Failure: Insights from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. PLoS ONE, 2014, 9, e113447.	1.1	15
457	Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696. Circulation: Heart Failure, 2014, 7, 953-959.	1.6	80
458	Skeletal myopathy in patients with chronic heart failure: significance of anabolic androgenic hormones. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 287-296.	2.9	69
459	Predictors of Postdischarge Outcomes From Information Acquired Shortly After Admission for Acute Heart Failure. Circulation: Heart Failure, 2014, 7, 76-87.	1.6	107
460	Normal electrocardiographic and echocardiographic (M-mode and two-dimensional) values in Polish Landrace pigs. Acta Veterinaria Scandinavica, 2014, 56, 54.	0.5	36
461	Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. European Heart Journal, 2014, 35, 2468-2476.	1.0	179
462	Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. European Heart Journal, 2014, 35, 1041-1050.	1.0	90
463	Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2014, 311, 252.	3.8	270
464	A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. European Heart Journal, 2014, 35, 431-441.	1.0	104
465	Rationale and design of the SOLuble guanylate Cyclase stimulator in heart failure Studies (SOCRATES). European Journal of Heart Failure, 2014, 16, 1026-1038.	2.9	119
466	EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. European Journal of Heart Failure, 2014, 16, 583-591.	2.9	99
467	2014 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2014, 46, 517-592.	0.6	2,164
468	Heart failure: preventing disease and death worldwide. ESC Heart Failure, 2014, 1, 4-25.	1.4	921

#	ARTICLE	IF	CITATIONS
469	Late-onset hypogonadism in men with systolic heart failure: prevalence, clinical associates, and impact on long-term survival. <i>ESC Heart Failure</i> , 2014, 1, 41-51.	1.4	5
470	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. <i>ESC Heart Failure</i> , 2014, 1, 52-58.	1.4	38
471	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. <i>European Heart Journal</i> , 2014, 35, 2383-2431.	1.0	1,253
472	Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from <sc>RELAX-HF</sc>. <i>European Journal of Heart Failure</i> , 2014, 16, 1230-1240.	2.9	134
473	Effect of Aloglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1515.	3.8	206
474	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD “Summary. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 133-173.	0.9	173
475	Psychological Gender of Men With Systolic Heart Failure. <i>American Journal of Men's Health</i> , 2014, 8, 249-257.	0.7	5
476	Immune and inflammation responses to a 3-day period of intensified running versus cycling. <i>Brain, Behavior, and Immunity</i> , 2014, 39, 180-185.	2.0	53
477	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. <i>European Heart Journal</i> , 2014, 35, 1284-1293.	1.0	276
478	Consequences of Peripheral Chemoreflex Inhibition with Low-Dose Dopamine in Humans. <i>Journal of Physiology</i> , 2014, , n/a-n/a.	1.3	1
479	Dissociation between blood pressure and heart rate response to hypoxia after bilateral carotid body removal in men with systolic heart failure. <i>Experimental Physiology</i> , 2014, 99, 552-561.	0.9	52
480	Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role. <i>European Journal of Heart Failure</i> , 2014, 16, 929-941.	2.9	83
481	Association of quality of life with anticoagulant control in patients with heart failure: The Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial. <i>International Journal of Cardiology</i> , 2014, 177, 715-717.	0.8	4
482	Recurrent Stroke in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. <i>Cerebrovascular Diseases</i> , 2014, 38, 176-181.	0.8	24
483	Comparison of clinical profile and management of outpatients with heart failure with reduced left ventricular ejection fraction treated by general practitioners and cardiologists in contemporary Poland: The results from the DATA-HELP registry. <i>International Journal of Cardiology</i> , 2014, 176, 852-858.	0.8	8
484	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 2733-2779.	1.0	3,469
485	Consequences of peripheral chemoreflex inhibition with low-dose dopamine in humans. <i>Journal of Physiology</i> , 2014, 592, 1295-1308.	1.3	34
486	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 401-408.	1.6	34

#	ARTICLE	IF	CITATIONS
487	Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 59-67.	1.6	60
488	Design and Rationale of the Soluble Guanylate Cyclase Stimulator in Heart Failure Studies (SOCRATES). <i>Journal of Cardiac Failure</i> , 2014, 20, S39.	0.7	0
489	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.	1.0	4,141
490	Considerable Regional Variation in AAV1 Neutralizing Antibodies and Its Consequences for a Multinational Clinical Trial of Gene Transfer for Advanced Heart Failure: The CUPID 2 Experience. <i>Journal of Cardiac Failure</i> , 2014, 20, S93.	0.7	0
491	2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. <i>European Heart Journal</i> , 2014, 35, 2873-2926.	1.0	3,549
492	Serum phosphorus level is related to degree of clinical response to up-titration of heart failure pharmacotherapy. <i>International Journal of Cardiology</i> , 2014, 177, 248-254.	0.8	6
493	Effect of Serelaxin on Mode of Death in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1591-1598.	1.2	56
494	Prevalence of Central Sleep Apnea in Patients Screened During the remedÄ® System Pilot Study. <i>Journal of Cardiac Failure</i> , 2014, 20, S117-S118.	0.7	0
495	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	1.0	2,591
496	Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. <i>International Journal of Cardiology</i> , 2014, 172, 588-594.	0.8	83
497	2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 58.	0.4	54
498	Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study. <i>International Journal of Cardiology</i> , 2014, 174, 268-275.	0.8	147
499	Liver Function, In-Hospital, and Post-Discharge Clinical Outcome in Patients With Acute Heart Failure—Results From the Relaxin for the Treatment of Patients With Acute Heart Failure Study. <i>Journal of Cardiac Failure</i> , 2014, 20, 407-413.	0.7	38
500	International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. <i>European Journal of Heart Failure</i> , 2014, 16, 614-624.	2.9	71
501	The additive burden of iron deficiency in the cardiorenal anaemia axis: scope of a problem and its consequences. <i>European Journal of Heart Failure</i> , 2014, 16, 655-662.	2.9	59
502	Effect of short-term rapid ventricular pacing followed by pacing interruption on arterial blood pressure in healthy pigs and pigs with tachycardiomyopathy. <i>Polish Journal of Veterinary Sciences</i> , 2014, 17, 85-91.	0.2	0
503	Improving care for patients with acute heart failure: before, during and after hospitalization. <i>ESC Heart Failure</i> , 2014, 1, 110-145.	1.4	222
504	Heart failure: preventing disease and death worldwide. <i>ESC Heart Failure</i> , 2014, 1, n/a-n/a.	1.4	5

#	ARTICLE	IF	CITATIONS
505	Testosterone deficiency in men with heart failure: pathophysiology and its clinical, prognostic and therapeutic implications. <i>Kardiologia Polska</i> , 2014, 72, 403-409.	0.3	7
506	Demographic and clinical characteristics of patients with atrial fibrillation and cardioversion as planned therapeutic options in the International Registry on Cardioversion of Atrial Fibrillation RHYTHM-AF Polish substudy. <i>Kardiologia Polska</i> , 2014, 72, 700-706.	0.3	3
507	Does right ventricular pacing increase the risk of ventricular arrhythmias in patients with an implantable cardioverter-defibrillator?. <i>Kardiologia Polska</i> , 2014, 72, 381-384.	0.3	0
508	Increase in heart failure mortality in Poland: can we explain the reasons?. <i>Polish Archives of Internal Medicine</i> , 2014, 124, 274-275.	0.3	0
509	Cardioversion of Atrial Fibrillation (RHYTHM-AF) International Registry in Poland. <i>Cardiology Journal</i> , 2014, 21, 484-491.	0.5	2
510	Hypercapnic Chemosensitivity in Patients with Heart Failure: Relation to Shifts in Type-1 Insulin-Like Growth Factor and Sex Hormone-Binding Globulin Levels. <i>Neurophysiology</i> , 2013, 45, 133-139.	0.2	0
511	Distance covered during a six-minute walk test predicts long-term cardiovascular mortality and hospitalisation rates in men with systolic heart failure: an observational study. <i>Journal of Physiotherapy</i> , 2013, 59, 177-187.	0.7	41
512	Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. <i>New England Journal of Medicine</i> , 2013, 369, 1206-1214.	13.9	1,201
513	Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis. <i>International Journal of Cardiology</i> , 2013, 168, 3878-3883.	0.8	30
514	Atrial Fibrillation Impairs the Diagnostic Performance of Cardiac Natriuretic Peptides in Dyspneic Patients. <i>JACC: Heart Failure</i> , 2013, 1, 192-199.	1.9	107
515	Iron deficiency in chronic heart failure: An international pooled analysis. <i>American Heart Journal</i> , 2013, 165, 575-582.e3.	1.2	532
516	Elevated serum lactate is a marker of organ damage related to impaired hemodynamics and indicates poor prognosis in acute heart failure. <i>European Heart Journal</i> , 2013, 34, P1517-P1517.	1.0	2
517	Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. <i>International Journal of Cardiology</i> , 2013, 168, 789-794.	0.8	22
518	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , 2013, 18, 107-122.	1.7	51
519	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. <i>European Journal of Heart Failure</i> , 2013, 15, 947-959.	2.9	75
520	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087.	1.0	1,758
521	Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. <i>European Heart Journal</i> , 2013, 34, 3128-3136.	1.0	56
522	Circulating testosterone and estradiol, autonomic balance and baroreflex sensitivity in middle-aged and elderly men with heart failure. <i>Aging Male</i> , 2013, 16, 58-66.	0.9	21

#	ARTICLE	IF	CITATIONS
523	Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex. <i>New England Journal of Medicine</i> , 2013, 369, 1395-1405.	13.9	688
524	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2013, 15, 456-464.	2.9	39
525	Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2013, 15, 679-689.	2.9	30
526	HIGH SOLUBLE TRANSFERRIN RECEPTOR IN PATIENTS WITH SYSTOLIC HEART FAILURE: A MEASURE OF IRON DEFICIENCY AND A STRONG PREDICTOR OF MORTALITY. <i>Journal of the American College of Cardiology</i> , 2013, 61, E749.	1.2	2
527	Management of Chronic Heart Failure – Update 2013. <i>Journal of Cardiac Failure</i> , 2013, 19, S109.	0.7	0
528	Predicting heart failure outcome from cardiac and comorbid conditions: The 3C-HF score. <i>International Journal of Cardiology</i> , 2013, 163, 206-211.	0.8	108
529	Changes in parasympathetic system in medulla oblongata in male pigs in the course of tachycardia-induced cardiomyopathy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2013, 177, 253-259.	1.4	2
530	Actualizaci3n detallada de las gu3as de la ESC para el manejo de la fibrilaci3n auricular de 2012. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 54.e1-54.e24.	0.6	14
531	Carotid body removal for treatment of chronic systolic heart failure. <i>International Journal of Cardiology</i> , 2013, 168, 2506-2509.	0.8	83
532	The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1973-1981.	1.2	159
533	Clinical Predictors and Hemodynamic Consequences of Elevated Peripheral Chemosensitivity in Optimally Treated Men With Chronic Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 408-415.	0.7	43
534	Treatment of Anemia with Darbeoetin Alfa in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2013, 368, 1210-1219.	13.9	462
535	Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program. <i>Journal of the American College of Cardiology</i> , 2013, 61, 196-206.	1.2	397
536	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Blood Pressure</i> , 2013, 22, 193-278.	0.7	355
537	Accuracy and Efficiency of Coupled-Cluster Theory Using Density Fitting/Cholesky Decomposition, Frozen Natural Orbitals, and a 1 -Transformed Hamiltonian. <i>Journal of Chemical Theory and Computation</i> , 2013, 9, 2687-2696.	2.3	131
538	Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. <i>Lancet</i> , The, 2013, 381, 29-39.	6.3	810
539	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2013, 34, 2159-2219.	1.0	5,681
540	Soluble guanylate cyclase: a potential therapeutic target for heart failure. <i>Heart Failure Reviews</i> , 2013, 18, 123-134.	1.7	118

#	ARTICLE	IF	CITATIONS
541	Sex-specific acute heart failure phenotypes and outcomes from PROTECT. <i>European Journal of Heart Failure</i> , 2013, 15, 1374-1381.	2.9	49
542	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	1.0	3,915
543	Gender-related differences in the clinical characteristics, pharmacotherapy and outcomes in the one-year follow-up in the Polish population of heart failure pilot survey. <i>European Heart Journal</i> , 2013, 34, P3340-P3340.	1.0	0
544	Low-dose dopamine infusion increases baroreflex sensitivity by inhibition of peripheral chemoreflex. <i>European Heart Journal</i> , 2013, 34, P2366-P2366.	1.0	0
545	Heart Failure with Preserved left ventricular Ejection Fraction (HFPEF) in the Polish population of the ESC EURObservational research programme: the heart failure pilot registry. <i>European Heart Journal</i> , 2013, 34, P2474-P2474.	1.0	0
546	Renal failure in patients with heart failure - analysis based on ESC-HF Pilot survey. <i>European Heart Journal</i> , 2013, 34, P645-P645.	1.0	3
547	Symptoms associated with male aging in men with systolic heart failure. <i>European Heart Journal</i> , 2013, 34, P5733-P5733.	1.0	0
548	Hypoglycaemia in diabetic patients: highly undesirable by cardiologists. <i>European Heart Journal</i> , 2013, 34, 3102-3105.	1.0	3
549	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). <i>Europace</i> , 2013, 15, 1070-1118.	0.7	908
550	Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. <i>European Heart Journal</i> , 2013, 34, 2453-2463.	1.0	419
551	Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial. <i>Emergency Medicine Journal</i> , 2013, 30, 633-637.	0.4	12
552	Expression and Complex Formation of MMP9, MMP2, NGAL, and TIMP1 in Porcine Myocardium but Not in Skeletal Muscles in Male Pigs with Tachycardia-Induced Systolic Heart Failure. <i>BioMed Research International</i> , 2013, 2013, 1-12.	0.9	23
553	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Journal of Hypertension</i> , 2013, 31, 1281-1357.	0.3	4,251
554	Value of serum pregnancy-associated plasma protein A for predicting cardiovascular events among patients presenting with cardiac chest pain. <i>Cmaj</i> , 2013, 185, E295-E303.	0.9	18
555	Iron status in patients with chronic heart failure. <i>European Heart Journal</i> , 2013, 34, 827-834.	1.0	212
556	Stroke in Heart Failure in Sinus Rhythm: The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction Trial. <i>Cerebrovascular Diseases</i> , 2013, 36, 74-78.	0.8	9
557	Anabolic deficiencies in men with systolic heart failure: do co-morbidities and therapies really contribute significantly?. <i>Aging Male</i> , 2013, 16, 123-131.	0.9	8
558	Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. <i>European Heart Journal</i> , 2013, 34, 816-829.	1.0	304

#	ARTICLE	IF	CITATIONS
559	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2013, 15, 1173-1184.	2.9	533
560	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013, 15, 1082-1094.	2.9	182
561	The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study. <i>European Journal of Heart Failure</i> , 2013, 15, 756-762.	2.9	27
562	Heart Failure in Patients With Atrial Fibrillation Is Associated With a High Symptom and Hospitalization Burden: The <sc>RealiseAF</sc> Survey. <i>Clinical Cardiology</i> , 2013, 36, 766-774.	0.7	23
563	Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1267-1276.	2.9	130
564	Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). <i>European Journal of Heart Failure</i> , 2013, 15, 334-341.	2.9	24
565	EUR<i>Observational</i> Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2013, 15, 808-817.	2.9	645
566	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2013, 34, 2281-2329.	1.0	2,176
567	Benefit of Warfarin Compared With Aspirin in Patients With Heart Failure in Sinus Rhythm. <i>Circulation: Heart Failure</i> , 2013, 6, 988-997.	1.6	38
568	The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. <i>European Heart Journal</i> , 2013, 34, 30-38.	1.0	139
569	Dopamine withdrawal causes chemoreflex-related increase in minute ventilation. <i>European Heart Journal</i> , 2013, 34, P576-P576.	1.0	0
570	Health locus of control and the sense of self-efficacy in patients with systolic heart failure: a pilot study. <i>Patient Preference and Adherence</i> , 2013, 7, 337.	0.8	19
571	Percutaneous reduction of mitral valve regurgitation using the MitraClip system – immediate and 90-day follow-up of 3 cases. <i>Postępy W Kardiologii Interwencyjnej</i> , 2013, 2, 126-131.	0.1	0
572	Sleep disordered breathing in patients with heart failure. <i>Cardiology Journal</i> , 2013, 20, 345-355.	0.5	13
573	Population of Polish patients participating in the Heart Failure Pilot Survey (ESC-HF Pilot). <i>Kardiologia Polska</i> , 2013, 71, 234-240.	0.3	11
574	Andropausal syndrome in men with systolic heart failure. <i>Polish Archives of Internal Medicine</i> , 2013, 123, 156-169.	0.3	4
575	Iron deficiency in patients with chronic kidney disease requiring hemodialysis: do inflammation and overexpressed hepcidin contribute significantly?. <i>Polish Archives of Internal Medicine</i> , 2013, 123, 68-70.	0.3	0
576	P-R interval in porcine model of chronic tachycardia-induced cardiomyopathy. <i>Bulletin of the Veterinary Institute in Pulawy = Biuletyn Instytutu Weterynarii W Pulawach</i> , 2013, 57, 437-441.	0.4	0

#	ARTICLE	IF	CITATIONS
577	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. <i>New England Journal of Medicine</i> , 2012, 367, 1297-1309.	13.9	765
578	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012, 33, 1787-1847.	1.0	5,233
579	Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 632-639.	2.1	259
580	Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. <i>European Journal of Heart Failure</i> , 2012, 14, 882-886.	2.9	71
581	Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. <i>European Journal of Heart Failure</i> , 2012, 14, 1056-1066.	2.9	105
582	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>European Journal of Heart Failure</i> , 2012, 14, 681-695.	2.9	71
583	Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. <i>European Journal of Heart Failure</i> , 2012, 14, 22-31.	2.9	46
584	Corrigendum to "Adherence of heart failure patients to exercise: barriers and possible solutions. A position statement of the Study Group on Exercise Training in Heart Failure of the Heart Failure Association of the European Society of Cardiology" [Eur J Heart Fail 2012;14:451-458]. <i>European Journal of Heart Failure</i> , 2012, 14, 802-802.	2.9	2
585	Rationale and design of ARTS: a randomized, double-blind study of BAY 948862 in patients with chronic heart failure and mild or moderate chronic kidney disease. <i>European Journal of Heart Failure</i> , 2012, 14, 668-675.	2.9	72
586	Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. <i>European Journal of Heart Failure</i> , 2012, 14, 782-790.	2.9	50
587	Adherence of heart failure patients to exercise: barriers and possible solutions. <i>European Journal of Heart Failure</i> , 2012, 14, 451-458.	2.9	263
588	The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. <i>European Journal of Heart Failure</i> , 2012, 14, 605-612.	2.9	115
589	Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. <i>European Journal of Heart Failure</i> , 2012, 14, 278-286.	2.9	122
590	Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. <i>Heart</i> , 2012, 98, 195-201.	1.2	109
591	Transvenous phrenic nerve stimulation for the treatment of central sleep apnoea in heart failure. <i>European Heart Journal</i> , 2012, 33, 889-894.	1.0	118
592	Relations between professional medical associations and the health-care industry, concerning scientific communication and continuing medical education: a Policy Statement from the European Society of Cardiology. <i>European Heart Journal</i> , 2012, 33, 666-674.	1.0	52
593	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1009-1022.	1.8	65
594	Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2012, 366, 20-33.	13.9	701

#	ARTICLE	IF	CITATIONS
595	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 2089-2099.	13.9	1,754
596	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 1387-1395.	6.3	990
597	Anticoagulation for Heart Failure Patients in Sinus Rhythm: Common in Clinical Practice But Still Not Evidence-based. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 687-689.	0.4	0
598	Relations between professional medical associations and healthcare industry, concerning scientific communication and continuing medical education: a Policy Statement from the European Society of Cardiology. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2012, 31, 529-538.	0.2	2
599	Anticoagulación para pacientes con insuficiencia cardiaca en ritmo sinusal: habitual en la práctica clínica, pero aún no basada en la evidencia. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 687-689.	0.6	1
600	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2012, 14, 1385-1413.	0.7	2,319
601	The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspnea. <i>Biomarkers</i> , 2012, 17, 490-497.	0.9	4
602	Relations between professional medical associations and healthcare industry, concerning scientific communication and continuing medical education: a Policy Statement from the European Society of Cardiology. <i>Revista Portuguesa De Cardiologia</i> , 2012, 31, 529-538.	0.2	3
603	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. <i>European Journal of Heart Failure</i> , 2012, 14, 803-869.	2.9	2,307
604	Design of the RELAXin in Acute Heart Failure Study. <i>American Heart Journal</i> , 2012, 163, 149-155.e1.	1.2	60
605	Phrenic Nerve Stimulation Improves Circulatory Delay in Patients With Heart Failure and Central Sleep Apnea. <i>Journal of Cardiac Failure</i> , 2012, 18, S14-S15.	0.7	0
606	Age, Clinical Characteristics and Outcomes of Patients With Acute Decompensated Heart Failure: Insights from the PROTECT Trial. <i>Journal of Cardiac Failure</i> , 2012, 18, S76.	0.7	0
607	RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 85.	0.7	19
608	The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment. <i>Drug Safety</i> , 2012, 35, 233-244.	1.4	40
609	Strategies for Multivessel Revascularization in Patients with Diabetes. <i>New England Journal of Medicine</i> , 2012, 367, 2375-2384.	13.9	1,573
610	Ursodeoxycholic Acid in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 585-592.	1.2	74
611	Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 366, 9-19.	13.9	1,681
612	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 938.e1-938.e59.	0.6	31

#	ARTICLE	IF	CITATIONS
613	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 2719-2747.	1.0	3,144
614	CoreValve transcatheter aortic valve implantation complicated by stress cardiomyopathy (tako-tsubo) and septic shock. <i>Postępy W Kardiologii Interwencyjnej</i> , 2012, 4, 335-337.	0.1	0
615	URSODEOXYCHOLIC ACID IN PATIENTS WITH CHRONIC HEART FAILURE. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER TRIAL. <i>Rational Pharmacotherapy in Cardiology</i> , 2012, 8, 110-117.	0.3	0
616	Coronary rotational atherectomy in patients with unsuccessful classical angioplasty " in-hospital and six-month follow-up. <i>Postępy W Kardiologii Interwencyjnej</i> , 2012, 2, 85-90.	0.1	0
617	Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. <i>New England Journal of Medicine</i> , 2012, 366, 1859-1869.	13.9	511
618	Vorapaxar in the Secondary Prevention of Atherothrombotic Events. <i>New England Journal of Medicine</i> , 2012, 366, 1404-1413.	13.9	841
619	Anemia in chronic heart failure: Can we treat? What to treat?. <i>Heart Failure Reviews</i> , 2012, 17, 203-210.	1.7	33
620	The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. <i>Clinical Research in Cardiology</i> , 2012, 101, 585-591.	1.5	38
621	Liver function tests in patients with acute heart failure. <i>Polish Archives of Internal Medicine</i> , 2012, 122, 471-479.	0.3	23
622	Costs of management of patients with coronary artery disease in Poland: the multicenter RECENT study. <i>Polish Archives of Internal Medicine</i> , 2012, 122, 599-607.	0.3	10
623	Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. <i>European Journal of Heart Failure</i> , 2011, 13, 961-967.	2.9	99
624	Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. <i>European Journal of Heart Failure</i> , 2011, 13, 347-357.	2.9	580
625	Effects of the Adenosine A1 Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1899-1907.	1.2	125
626	Midregion Prohormone Adrenomedullin and Prognosis in Patients Presenting With Acute Dyspnea. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1057-1067.	1.2	128
627	Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2011, 364, 907-917.	13.9	741
628	Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2011, 365, 32-43.	13.9	1,133
629	The PROTECT In-Hospital Risk Model: 7-Day Outcome in Patients Hospitalized with Acute Heart Failure (AHF) and Renal Dysfunction. <i>Journal of Cardiac Failure</i> , 2011, 17, S77.	0.7	0
630	Iron Deficiency Predicts Impaired Exercise Capacity in Patients With Systolic Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2011, 17, 899-906.	0.7	227

#	ARTICLE	IF	CITATIONS
631	Development of porcine model of chronic tachycardia-induced cardiomyopathy. <i>International Journal of Cardiology</i> , 2011, 153, 36-41.	0.8	19
632	Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. <i>Nature Reviews Cardiology</i> , 2011, 8, 485-493.	6.1	175
633	Effect on Mode of Death of Heart Failure Treatment Started with Bisoprolol Followed by Enalapril, Compared to the Opposite Order: Results of the Randomized CIBIS III Trial. <i>Cardiovascular Therapeutics</i> , 2011, 29, 89-98.	1.1	15
634	International Differences in Acute Heart Failure (AHF) Patients: Insight from the PROTECT Trial. <i>Journal of Cardiac Failure</i> , 2011, 17, S59-S60.	0.7	0
635	Japanese-Western Consensus Meeting on Biomarkers. <i>International Heart Journal</i> , 2011, 52, 253-265.	0.5	20
636	Single Night Transvenous Phrenic Nerve Stimulation Improves Central Sleep Apnoea In Systolic Heart Failure. , 2011, , .		0
637	Comparison of invasive and non-invasive measurements of haemodynamic parameters in patients with advanced heart failure. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 773-778.	0.6	39
638	Short-term Mortality Risk in Emergency Department Acute Heart Failure. <i>Academic Emergency Medicine</i> , 2011, 18, 947-958.	0.8	64
639	Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2011, 100, 745-753.	1.5	12
640	Changes in autonomic balance in patients with decompensated chronic heart failure. <i>Clinical Autonomic Research</i> , 2011, 21, 47-54.	1.4	27
641	Biomarkers in kidney and heart disease. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 62-74.	0.4	46
642	Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2011, 13, 1-10.	2.9	350
643	Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2011, 13, 1058-1058.	0.7	4
644	'Iron deficiency: an ominous sign in patients with systolic chronic heart failure' [Eur Heart J 2010;31:1872-1880, doi:10.1093/eurheartj/ehq158]. <i>European Heart Journal</i> , 2011, 32, 1054-1054.	1.0	4
645	Anemia in heart failure: an overview of current concepts. <i>Future Cardiology</i> , 2011, 7, 119-129.	0.5	16
646	Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin. <i>Circulation: Heart Failure</i> , 2011, 4, 613-620.	1.6	165
647	Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 724-732.	1.6	82
648	Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. <i>European Heart Journal</i> , 2011, 32, 1519-1534.	1.0	84

#	ARTICLE	IF	CITATIONS
649	Identification of Chronic Heart Failure Patients with a High 12-Month Mortality Risk Using Biomarkers Including Plasma C-Terminal Pro-Endothelin-1. PLoS ONE, 2011, 6, e14506.	1.1	34
650	Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. European Journal of Heart Failure, 2010, 12, 499-507.	2.9	59
651	Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. Circulation: Heart Failure, 2010, 3, 314-325.	1.6	134
652	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. European Journal of Anaesthesiology, 2010, 27, 92-137.	0.7	263
653	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet, The, 2010, 376, 875-885.	6.3	2,119
654	Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Journal of Cachexia, Sarcopenia and Muscle, 2010, 1, 187-194.	2.9	75
655	Treatment of Anemia With Darbepoetin Alfa in Heart Failure. Congestive Heart Failure, 2010, 16, 87-95.	2.0	6
656	Treating in-stent restenosis with drug-eluting balloon with intracoronary ultrasound control, with later optical coherent tomography control. Postępy W Kardiologii Interwencyjnej, 2010, 4, 203-207.	0.1	0
657	Long-term time-course of nocturnal breathing disorders in heart failure patients. European Respiratory Journal, 2010, 35, 361-367.	3.1	11
658	2010 Focused Update of ESC Guidelines on device therapy in heart failure. European Journal of Heart Failure, 2010, 12, 1143-1153.	2.9	152
659	Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. European Journal of Heart Failure, 2010, 12, 1130-1139.	2.9	88
660	Deficiencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure. European Journal of Heart Failure, 2010, 12, 966-973.	2.9	31
661	Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. European Journal of Heart Failure, 2010, 12, 1238-1246.	2.9	15
662	Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dialysis Transplantation, 2010, 25, 1416-1420.	0.4	118
663	Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dialysis Transplantation, 2010, 25, 1777-1784.	0.4	31
664	Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dialysis Transplantation, 2010, 25, 1406-1416.	0.4	188
665	EUR-Observer Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). European Journal of Heart Failure, 2010, 12, 1076-1084.	2.9	340
666	Iron deficiency: an ominous sign in patients with systolic chronic heart failure. European Heart Journal, 2010, 31, 1872-1880.	1.0	515

#	ARTICLE	IF	CITATIONS
667	Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 239-248.	2.9	214
668	Management of Chronic Cardiorenal Syndrome. <i>Contributions To Nephrology</i> , 2010, 165, 129-139.	1.1	7
669	Cardiorenal Syndromes – Recommendations from Clinical Practice Guidelines: The Cardiologist’s View. <i>Contributions To Nephrology</i> , 2010, 165, 145-152.	1.1	9
670	Corrigendum to: ‘Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA)’ [<i>Eur Heart J</i> 2009;30:2769-2812]. <i>European Heart Journal</i> , 2010, 31, 379-379.	1.0	1
671	Heart Failure Classifications – Guidelines. <i>Contributions To Nephrology</i> , 2010, 164, 11-23.	1.1	4
672	Acute Heart Failure Clinical Drug Development: From Planning to Proof of Activity to Phase III. <i>Cardiology</i> , 2010, 116, 292-301.	0.6	11
673	Low Lymphocyte Ratio as a Novel Prognostic Factor in Acute Heart Failure: Results from the Pre-RELAX-AHF Study. <i>Cardiology</i> , 2010, 117, 190-196.	0.6	17
674	EPO’s rescue mission in acute myocardial infarction: still more hopes than evidence. <i>European Heart Journal</i> , 2010, 31, 2577-2579.	1.0	8
675	Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 484-491.	2.9	117
676	Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. <i>European Journal of Heart Failure</i> , 2010, 12, 423-433.	2.9	593
677	Cardiorenal Syndromes: An Executive Summary from the Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , 2010, 165, 54-67.	1.1	106
678	Physician-Determined Worsening Heart Failure: A Novel Definition for Early Worsening Heart Failure in Patients Hospitalized for Acute Heart Failure – Association with Signs and Symptoms, Hospitalization Duration, and 60-Day Outcomes. <i>Cardiology</i> , 2010, 115, 29-36.	0.6	45
679	Molecular Changes in Myocardium in the Course of Anemia or Iron Deficiency. <i>Heart Failure Clinics</i> , 2010, 6, 295-304.	1.0	40
680	Nutritional Recommendations for the Management of Sarcopenia. <i>Journal of the American Medical Directors Association</i> , 2010, 11, 391-396.	1.2	548
681	Mid-Region Pro-Hormone Markers for Diagnosis and Prognosis in Acute Dyspnea. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2062-2076.	1.2	467
682	Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2010, 31, 2369-2429.	1.0	4,635
683	Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. <i>International Journal of Cardiology</i> , 2010, 143, 343-348.	0.8	40
684	Design and Rationale of the PROTECT Study: A Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function. <i>Journal of Cardiac Failure</i> , 2010, 16, 25-35.	0.7	76

#	ARTICLE	IF	CITATIONS
685	The Effects of Adenosine A1 Receptor Antagonism in Patients With Acute Decompensated Heart Failure and Worsening Renal Function: The REACH UP Study. <i>Journal of Cardiac Failure</i> , 2010, 16, 714-719.	0.7	22
686	2010 Focused Update of ESC Guidelines on device therapy in heart failure. <i>Europace</i> , 2010, 12, 1526-1536.	0.7	297
687	Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. <i>New England Journal of Medicine</i> , 2010, 363, 905-917.	13.9	791
688	Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. <i>European Heart Journal</i> , 2010, 31, 703-711.	1.0	797
689	Rolofylline, an Adenosine A ₁ Receptor Antagonist, in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2010, 363, 1419-1428.	13.9	473
690	2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. <i>European Heart Journal</i> , 2010, 31, 2677-2687.	1.0	427
691	Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2010, 12, 1360-1420.	0.7	1,360
692	ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2077-2089.	0.4	35
693	Reduced Circulating Levels of Testosterone and Insulin-Like Growth Factor Predict the Prevalence of Hyperuricaemia, the Major Cardiovascular Risk Factor, in Men with Systolic Chronic Heart Failure.. , 2010, , P1-402-P1-402.		0
694	Determinants of physical fitness in males with systolic heart failure. <i>Kardiologia Polska</i> , 2010, 68, 146-54.	0.3	7
695	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2009, 11, 119-129.	2.9	281
696	Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. <i>European Heart Journal</i> , 2009, 30, 1331-1339.	1.0	85
697	Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2009, 360, 2176-2190.	13.9	459
698	Defibrillator Implantation Early after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2009, 361, 1427-1436.	13.9	605
699	Circulating Estradiol and Mortality in Men With Systolic Chronic Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1892.	3.8	88
700	Corrigendum to "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008" [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. <i>European Journal of Heart Failure</i> , 2009, 11, 110-110.	2.9	4
701	Home telemonitoring in heart failure patients: the HHH study (Home or Hospital in Heart Failure). <i>European Journal of Heart Failure</i> , 2009, 11, 312-318.	2.9	130
702	Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2009, 11, 433-443.	2.9	449

#	ARTICLE	IF	CITATIONS
703	The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. <i>European Journal of Heart Failure</i> , 2009, 11, 1071-1077.	2.9	27
704	Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants. <i>European Journal of Heart Failure</i> , 2009, 11, 28-38.	2.9	54
705	Pathophysiological and clinical relevance of simplified monitoring of nocturnal breathing disorders in heart failure patients. <i>European Journal of Heart Failure</i> , 2009, 11, 264-272.	2.9	18
706	Rationale and design of Ferinject® Assessment in patients with Iron deficiency and chronic Heart Failure (FAIRâ€CHF) study: a randomized, placeboâ€controlled study of intravenous iron supplementation in patients with and without anaemia. <i>European Journal of Heart Failure</i> , 2009, 11, 1084-1091.	2.9	105
707	Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (REDâ€CHF): a Phase III, anaemia correction, morbidityâ€mortality trial. <i>European Journal of Heart Failure</i> , 2009, 11, 795-801.	2.9	107
708	Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. <i>European Heart Journal</i> , 2009, 30, 540-548.	1.0	286
709	ESPEN Guidelines on Parenteral Nutrition: On Cardiology and Pneumology. <i>Clinical Nutrition</i> , 2009, 28, 455-460.	2.3	53
710	European silver paper on the future of health promotion and preventive actions, basic research, and clinical aspects of age-related disease. <i>European Journal of Ageing</i> , 2009, 6, 51-57.	1.2	13
711	A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2009, 361, 2019-2032.	13.9	2,110
712	Large Animal Models of Heart Failure. <i>Circulation: Heart Failure</i> , 2009, 2, 262-271.	1.6	267
713	Rationale and Design of a Prospective Trial to Assess the Sensitivity and Positive Predictive Value of Implantable Intrathoracic Impedance Monitoring in the Prediction of Heart Failure Hospitalizations: The SENSE-HF Study. <i>Journal of Cardiac Failure</i> , 2009, 15, 394-400.	0.7	19
714	Reduction in Circulating Testosterone Relates to Exercise Capacity in Men With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2009, 15, 442-450.	0.7	87
715	Vasodilators in Acute Heart Failure (AHF): Does Blood Pressure Matter? Results from Pre-Relax-AHF. <i>Journal of Cardiac Failure</i> , 2009, 15, S74.	0.7	2
716	Changes in Dyspnea during Treatment of Acute Heart Failure Are Correlated with Clinical Signs, Rehospitalizations and Mortality. Results from the Pre-RELAX-AHF Trial. <i>Journal of Cardiac Failure</i> , 2009, 15, S62-S63.	0.7	3
717	Worsening Renal Function in Acute Heart Failure: Change in Blood Pressure and Effects of Relaxin. <i>Journal of Cardiac Failure</i> , 2009, 15, S63.	0.7	0
718	Time to Treatment and Vasodilator Efficacy in Acute Heart Failure: Results from the Pre-RELAX-AHF Study. <i>Journal of Cardiac Failure</i> , 2009, 15, S68.	0.7	1
719	Troponin Release in Patients Admitted with Acute Decompensated Heart Failure and Renal Dysfunction: Results from the Pilot Phase of the PROTECT Trial. <i>Journal of Cardiac Failure</i> , 2009, 15, S36-S37.	0.7	0
720	Erythropoietin levels in heart failure after an acute myocardial infarction: Determinants, prognostic value, and the effects of captopril versus losartan. <i>American Heart Journal</i> , 2009, 157, 91-96.	1.2	13

#	ARTICLE	IF	CITATIONS
721	Standardizing care for acute decompensated heart failure in a large megatrial: The approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2009, 157, 219-228.	1.2	36
722	Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. <i>American Heart Journal</i> , 2009, 158, 896-901.e3.	1.2	184
723	Sex Hormone-Binding Globulin and Heart Failure: a Passive Carrier of Steroid Hormones or an Active Hormone Itself?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 1353-1355.	0.4	4
724	Guía de práctica clínica para la valoración del riesgo cardiaco preoperatorio y el manejo cardiaco perioperatorio en la cirugía no cardiaca. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 1467.e1-1467.e56.	0.4	0
725	Silver paper: The future of health promotion and preventive actions, basic research, and clinical aspects of age-related disease. <i>Aging Clinical and Experimental Research</i> , 2009, 21, 376-385.	1.4	50
726	Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. <i>New England Journal of Medicine</i> , 2009, 361, 2436-2448.	13.9	1,633
727	Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. <i>Lancet, The</i> , 2009, 373, 1429-1439.	6.3	387
728	Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. <i>Lancet, The</i> , 2009, 374, 29-38.	6.3	611
729	Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. <i>Lancet, The</i> , 2009, 373, 2125-2135.	6.3	1,243
730	Guía de práctica clínica para la valoración del riesgo cardiaco preoperatorio y el manejo cardiaco perioperatorio en la cirugía no cardiaca. <i>Revista Espanola De Cardiologia</i> , 2009, 62, 1467.e1-1467.e56.	0.6	7
731	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Heart Journal</i> , 2009, 30, 2769-2812.	1.0	735
732	Abnormal indices of autonomic function are no longer predictors of poor outcome in diabetic patients without neuropathy but with coexisting coronary artery disease who receive optimal pharmacological therapy. <i>Kardiologia Polska</i> , 2009, 67, 1325-32.	0.3	2
733	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). <i>European Heart Journal</i> , 2008, 29, 2388-2442.	1.0	2,656
734	Cachexia: A new definition. <i>Clinical Nutrition</i> , 2008, 27, 793-799.	2.3	1,906
735	ESC Guidelines for the Diagnosis And Treatment of Acute And Chronic Heart Failure 2008. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008, 61, 1329.	0.4	12
736	Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency. <i>Journal of the American College of Cardiology</i> , 2008, 51, 103-112.	1.2	488
737	Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2276-2285.	1.2	145
738	Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2008, 359, 2456-2467.	13.9	1,663

#	ARTICLE	IF	CITATIONS
739	Lack of decrease in plasma N-terminal pro-brain natriuretic peptide identifies acute heart failure patients with very poor outcome. <i>International Journal of Cardiology</i> , 2008, 129, 373-378.	0.8	13
740	The 12-week progressive quadriceps resistance training improves muscle strength, exercise capacity and quality of life in patients with stable chronic heart failure. <i>International Journal of Cardiology</i> , 2008, 130, 36-43.	0.8	63
741	Dronedaron for the control of ventricular rate in permanent atrial fibrillation: The Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) study. <i>American Heart Journal</i> , 2008, 156, 527.e1-527.e9.	1.2	197
742	Hematinics in Patients with Complicated Acute Myocardial Infarction: Results from an OPTIMAAL Substudy. <i>Journal of Cardiac Failure</i> , 2008, 14, S34.	0.7	0
743	Prognostic Value of Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure (CHF). <i>Journal of Cardiac Failure</i> , 2008, 14, S90.	0.7	0
744	The PROTECT Pilot Study: A Randomized, Placebo-Controlled, Dose-Finding Study of the Adenosine A1 Receptor Antagonist Rolofylline in Patients With Acute Heart Failure and Renal Impairment. <i>Journal of Cardiac Failure</i> , 2008, 14, 631-640.	0.7	160
745	Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. <i>Lancet, The</i> , 2008, 371, 228-236.	6.3	159
746	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008, 372, 807-816.	6.3	934
747	Corrigendum to "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008" [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. <i>European Heart Journal</i> , 2008, 29, 3069-3069.	1.0	47
748	Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. <i>European Journal of Heart Failure</i> , 2008, 10, 140-148.	2.9	134
749	Increased Mortality after Dronedaron Therapy for Severe Heart Failure. <i>New England Journal of Medicine</i> , 2008, 358, 2678-2687.	13.9	901
750	Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. <i>European Heart Journal</i> , 2008, 30, 478-486.	1.0	247
751	Facilitated PCI in Patients with ST-Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2008, 358, 2205-2217.	13.9	596
752	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. <i>European Journal of Heart Failure</i> , 2008, 10, 933-989.	2.9	1,893
753	Rationale and Design of the Hemodynamic, Echocardiographic and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: A Randomized Controlled Trial in Patients Hospitalized With Heart Failure (HORIZON-HF) Trial. <i>American Journal of Therapeutics</i> , 2008, 15, 231-240.	0.5	16
754	Combined testosterone and insulin-like growth factor deficiency impairs quadriceps strength in men with chronic heart failure. <i>European Journal of Heart Failure, Supplement</i> , 2008, 7, 2-3.	0.2	1
755	Sexual complaints in men with chronic heart failure: prevalence and hormone determinants. <i>European Journal of Heart Failure, Supplement</i> , 2008, 7, 118-118.	0.2	0
756	Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2007, 9, 684-694.	2.9	335

#	ARTICLE	IF	CITATIONS
757	Response to Letter Regarding Article, "Anabolic Deficiency in Men With Chronic Heart Failure: Prevalence and Detrimental Impact on Survival"; Circulation, 2007, 115, .	1.6	1
758	Excessive ventilation during early phase of exercise: A new predictor of poor long-term outcome in patients with chronic heart failure. European Journal of Heart Failure, 2007, 9, 1024-1031.	2.9	16
759	Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. European Heart Journal, 2007, 28, 821-828.	1.0	86
760	Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. European Heart Journal, 2007, 28, 2208-2216.	1.0	184
761	679 Reduction in serum testosterone deteriorates exercise capacity in men in the course of chronic heart failure. European Journal of Heart Failure, Supplement, 2007, 6, 148-148.	0.2	2
762	Treatment of advanced chronic heart failure with normal left ventricular ejection fraction. Response to the letter by Dr. Martinez-Selles. European Journal of Heart Failure, 2007, 9, 1224-1225.	2.9	2
763	2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187.	0.3	4,778
764	A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clinical Science, 2007, 113, 205-212.	1.8	210
765	Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. International Journal of Cardiology, 2007, 115, 151-155.	0.8	65
766	Nuclear factor-kappaB activity in peripheral blood mononuclear cells in cachectic and non-cachectic patients with chronic heart failure. International Journal of Cardiology, 2007, 122, 111-116.	0.8	14
767	Home telemonitoring of vital signs and cardiorespiratory signals in heart failure patients: System architecture and feasibility of the HHH model. International Journal of Cardiology, 2007, 120, 371-379.	0.8	25
768	Hyperhomocysteinemia in patients with symptomatic chronic heart failure: Prevalence and prognostic importance—pilot study. Atherosclerosis, 2007, 194, 408-414.	0.4	28
769	2007 ESH-ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2007, 16, 135-232.	0.7	292
770	Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 49, 753-762.	1.2	203
771	Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 50, 1054-1060.	1.2	397
772	Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 50, 1973-1980.	1.2	139
773	677 Does andropause exist in men with chronic heart failure, and is it linked to multiple anabolic deficiency?. European Journal of Heart Failure, Supplement, 2007, 6, 147-148.	0.2	0
774	542 Pentoxifylline improves the haemoglobin levels in anaemic patients with chronic heart failure. European Journal of Heart Failure, Supplement, 2007, 6, 124-124.	0.2	0

#	ARTICLE	IF	CITATIONS
775	343 Depression in men with chronic heart failure: prevalence and hormone determinants. <i>European Journal of Heart Failure, Supplement, 2007, 6, 78-78.</i>	0.2	0
776	245 Prognostic utility of growth-differentiation factor-15 in patients with chronic heart failure. <i>European Journal of Heart Failure, Supplement, 2007, 6, 46-47.</i>	0.2	0
777	857 Serum hepcidin is not linked to iron status in patients with chronic heart failure. <i>European Journal of Heart Failure, Supplement, 2007, 6, 186-186.</i>	0.2	0
778	75 Oscillatory ventilation at rest coexisting with increased ventilatory response to exercise allow to identify heart failure patients with very poor outcome. <i>European Journal of Heart Failure, Supplement, 2007, 6, 15-15.</i>	0.2	0
779	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal, 2006, 28, 1462-1536.</i>	1.0	1,617
780	EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. <i>European Heart Journal, 2006, 27, 2725-2736.</i>	1.0	1,063
781	Intravenous Iron Sucrose in Anemic and Non-anemic Iron Deficient Patients with CHF: A Randomized, Controlled, Observer-blinded Intervention Study (FERRIC-HF). <i>Journal of Cardiac Failure, 2006, 12, S179.</i>	0.7	1
782	Statin use and survival in patients with chronic heart failure – results from two observational studies with 5200 patients. <i>International Journal of Cardiology, 2006, 112, 234-242.</i>	0.8	90
783	Rationale and design of CIBIS III. <i>Country Review Ukraine, 2006, 8, C35-C42.</i>	0.8	0
784	ESPEN Guidelines on Enteral Nutrition: Cardiology and Pulmonology. <i>Clinical Nutrition, 2006, 25, 311-318.</i>	2.3	128
785	Autonomic imbalance and immune activation in chronic heart failure – Pathophysiological links. <i>Cardiovascular Research, 2006, 70, 434-445.</i>	1.8	109
786	Anabolic Deficiency in Men With Chronic Heart Failure. <i>Circulation, 2006, 114, 1829-1837.</i>	1.6	346
787	Reduced Peripheral Skeletal Muscle Mass and Abnormal Reflex Physiology in Chronic Heart Failure. <i>Circulation, 2006, 114, 126-134.</i>	1.6	135
788	Persistent high NTpro-BNP concentration as a negative prognostic factor in patients with decompensated heart failure. <i>Kardiologia Polska, 2006, 64, 250-6; discussion 257-8.</i>	0.3	4
789	Activation of the NF- κ B system in peripheral blood leukocytes from patients with chronic heart failure. <i>European Journal of Heart Failure, 2005, 7, 984-990.</i>	2.9	20
790	Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence. <i>Circulation, 2005, 112, 2426-2435.</i>	1.6	305
791	Impaired Insulin Sensitivity as an Independent Risk Factor for Mortality in Patients With Stable Chronic Heart Failure. <i>Journal of the American College of Cardiology, 2005, 46, 1019-1026.</i>	1.2	249
792	Beta-Blocker Treatment Before Angiotensin-Converting Enzyme Inhibitor Therapy in Newly Diagnosed Heart Failure. <i>Journal of the American College of Cardiology, 2005, 46, 182.</i>	1.2	1

#	ARTICLE	IF	CITATIONS
793	A multi-country randomised trial of the role of a new telemonitoring system in CHF: the HHH study (Home or Hospital in Heart Failure). Rational, study design and protocol. <i>European Heart Journal Supplements</i> , 2004, 6, F99-F102.	0.0	9
794	Editorial comment on effect of exercise training in patients with heart failure. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2004, 11, 168-170.	3.1	0
795	Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III. <i>European Journal of Heart Failure</i> , 2004, 6, 493-500.	2.9	30
796	Effect of anemia on exercise tolerance in chronic heart failure in men. <i>American Journal of Cardiology</i> , 2003, 91, 888-891.	0.7	125
797	Effect of carvedilol on exercise tolerance in patients with chronic heart failure and a restrictive left ventricular filling pattern. <i>American Journal of Cardiology</i> , 2003, 91, 1281-1283.	0.7	3
798	The association of lower testosterone level with coronary artery disease in postmenopausal women. <i>International Journal of Cardiology</i> , 2003, 87, 53-57.	0.8	32
799	Uric Acid and Survival in Chronic Heart Failure. <i>Circulation</i> , 2003, 107, 1991-1997.	1.6	532
800	1350 Ergoreflex contribution to ventilatory response assessed during exercise of forearm and quadriceps muscles in patients with chronic heart failure. <i>European Heart Journal</i> , 2003, 24, 259.	1.0	0
801	P1581 Ventilatory response to early phase of exercise: a novel index useful for the comprehensive assessment of patients with chronic heart failure. <i>European Heart Journal</i> , 2003, 24, 288.	1.0	0
802	1347 Excessive ventilation during early phase of exercise predicts poor outcome in patients with chronic heart failure. <i>European Heart Journal</i> , 2003, 24, 258.	1.0	0
803	3635 Statin therapy and survival in 2068 chronic heart failure patients: ischaemic versus non-ischaemic etiology. <i>European Heart Journal</i> , 2003, 24, 708.	1.0	0
804	2594 The activation of the nuclear factor- κ B system in chronic heart failure. <i>European Heart Journal</i> , 2003, 24, 488.	1.0	0
805	P3243 Endotoxin inhibits apoptosis in ex vivo mononuclear blood cells from patients with chronic heart failure. <i>European Heart Journal</i> , 2003, 24, 611.	1.0	0
806	853 In chronic heart failure overactive chemokine system is associated with immune activation, low grade inflammation and predicts loss of fat tissue. <i>European Heart Journal</i> , 2003, 24, 145.	1.0	0
807	1453 In majority of patients with intermediate coronary lesions increased doses of intracoronary adenosine are required for the reliable assessment of fractional flow reserve. <i>European Heart Journal</i> , 2003, 24, 264.	1.0	1
808	1929 Insulin resistance predicts impaired survival in chronic heart failure. <i>European Heart Journal</i> , 2003, 24, 362.	1.0	0
809	The role of exercise ventilation in clinical evaluation and risk stratification in patients with chronic heart failure. <i>Kardiologia Polska</i> , 2003, 59, 115-27; commentary 126-7.	0.3	5
810	Impact of periodic breathing on measurement of oxygen uptake and respiratory exchange ratio during cardiopulmonary exercise testing. <i>Clinical Science</i> , 2002, 103, 543-552.	1.8	19

#	ARTICLE	IF	CITATIONS
811	PRESTO (a mammoth trial that could have been prevented), HPS and REMATCH. <i>International Journal of Cardiology</i> , 2002, 83, 99-102.	0.8	1
812	Peripheral Chemoreceptor Hypersensitivity. <i>Circulation</i> , 2001, 104, 544-549.	1.6	264
813	Effect of altering conditions of the sequence method on baroreflex sensitivity. <i>Journal of Hypertension</i> , 2001, 19, 1279-1287.	0.3	39
814	Relation of heart rate and blood pressure turbulence following premature ventricular complexes to baroreflex sensitivity in chronic congestive heart failure. <i>American Journal of Cardiology</i> , 2001, 87, 737-742.	0.7	123
815	Enhanced Ventilatory Response to Exercise in Patients With Chronic Heart Failure and Preserved Exercise Tolerance. <i>Circulation</i> , 2001, 103, 967-972.	1.6	348
816	Muscle Ergoreceptor Overactivity Reflects Deterioration in Clinical Status and Cardiorespiratory Reflex Control in Chronic Heart Failure. <i>Circulation</i> , 2001, 104, 2324-2330.	1.6	208
817	Very-low-frequency oscillations in heart rate and blood pressure in periodic breathing: role of the cardiovascular limb of the hypoxic chemoreflex. <i>Clinical Science</i> , 2000, 99, 125.	1.8	9
818	Very-low-frequency oscillations in heart rate and blood pressure in periodic breathing: role of the cardiovascular limb of the hypoxic chemoreflex. <i>Clinical Science</i> , 2000, 99, 125-132.	1.8	21
819	Contribution of skeletal muscle "ergoreceptors"™ in the human leg to respiratory control in chronic heart failure. <i>Journal of Physiology</i> , 2000, 529, 863-870.	1.3	86
820	Echocardiographic determinants of mortality in patients >67 years of age with chronic heart failure. <i>American Journal of Cardiology</i> , 2000, 86, 158-161.	0.7	21
821	Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO ₂ slope and peak VO ₂ . <i>European Heart Journal</i> , 2000, 21, 154-161.	1.0	452
822	Prognostic value of changes over time in exercise capacity and echocardiographic measurements in patients with chronic heart failure. <i>European Heart Journal</i> , 2000, 21, 146-153.	1.0	69
823	Chronic heart failure in the elderly: value of cardiopulmonary exercise testing in risk stratification. <i>British Heart Journal</i> , 2000, 83, 147-151.	2.2	65
824	Cardiac autonomic dysfunction in AIDS is not secondary to heart failure. <i>International Journal of Cardiology</i> , 2000, 74, 133-137.	0.8	33
825	The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. <i>Journal of the American College of Cardiology</i> , 2000, 36, 523-528.	1.2	60
826	Chemoreceptor-Baroreceptor Interactions in Cardiovascular Disease. <i>Lung Biology in Health and Disease</i> , 2000, , 33-60.	0.1	7
827	Origin of Oscillatory Kinetics of Respiratory Gas Exchange in Chronic Heart Failure. <i>Circulation</i> , 1999, 100, 1065-1070.	1.6	44
828	Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. <i>European Heart Journal</i> , 1999, 20, 683-693.	1.0	321

#	ARTICLE	IF	CITATIONS
829	Oscillatory Breathing Patterns During Wakefulness in Patients With Chronic Heart Failure. <i>Circulation</i> , 1999, 100, 2418-2424.	1.6	196
830	Usefulness of the P Wave Signal-Averaged Electrocardiogram in Predicting Patients at Risk of Atrial Flutter and Fibrillation Induced by Transesophageal Pacing. <i>Annals of Noninvasive Electrocardiology</i> , 1999, 4, 46-52.	0.5	1
831	Effects of amiodarone on the P-wave triggered signal-averaged electrocardiogram in patients with paroxysmal atrial fibrillation and coronary artery disease. <i>American Journal of Cardiology</i> , 1999, 83, 112-114.	0.7	27
832	Impact of periodic breathing on and : a quantitative approach by Fourier analysis. <i>Respiration Physiology</i> , 1999, 118, 247-255.	2.8	8
833	A neural link to explain the "muscle hypothesis" of exercise intolerance in chronic heart failure. <i>American Heart Journal</i> , 1999, 137, 1050-1056.	1.2	126
834	The impact of cachexia on cardiorespiratory reflex control in chronic heart failure. <i>European Heart Journal</i> , 1999, 20, 1667-1675.	1.0	38
835	Comparison between spectral analysis and the phenylephrine method for the assessment of baroreflex sensitivity in chronic heart failure. <i>Clinical Science</i> , 1999, 97, 503-513.	1.8	30
836	Comparison between spectral analysis and the phenylephrine method for the assessment of baroreflex sensitivity in chronic heart failure. <i>Clinical Science</i> , 1999, 97, 503.	1.8	18
837	Aetiology and pathophysiological implications of oscillatory ventilation at rest and during exercise in chronic heart failure. Do Cheyne and Stokes have an important message for modern-day patients with heart failure?. <i>European Heart Journal</i> , 1999, 20, 946-953.	1.0	52
838	Ventilatory response to exercise correlates with impaired heart rate variability in patients with chronic congestive heart failure. <i>American Journal of Cardiology</i> , 1998, 82, 338-344.	0.7	60
839	Impaired baroreflex sensitivity and sympathovagal balance in syndrome X. <i>American Journal of Cardiology</i> , 1998, 82, 862-868.	0.7	39
840	Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure. <i>International Journal of Cardiology</i> , 1998, 66, 1-10.	0.8	54
841	Wasting as independent risk factor for mortality in chronic heart failure. <i>Lancet</i> , The, 1997, 349, 1050-1053.	6.3	1,209
842	Effects of Dihydrocodeine on Chemosensitivity and Exercise Tolerance in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 1997, 29, 147-152.	1.2	136
843	Clinical Correlates and Prognostic Significance of the Ventilatory Response to Exercise in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 1997, 29, 1585-1590.	1.2	505
844	Skeletal Muscle Function and Its Relation to Exercise Tolerance in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 1997, 30, 1758-1764.	1.2	352
845	Depressed Heart Rate Variability as an Independent Predictor of Death in Chronic Congestive Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy. <i>American Journal of Cardiology</i> , 1997, 79, 1645-1650.	0.7	436
846	Effect of Estrogen Replacement Therapy on Heart Rate Variability and Heart Rate in Healthy Postmenopausal Women. <i>American Journal of Cardiology</i> , 1997, 80, 815-817.	0.7	101

#	ARTICLE	IF	CITATIONS
847	Hormonal Changes and Catabolic/Anabolic Imbalance in Chronic Heart Failure and Their Importance for Cardiac Cachexia. <i>Circulation</i> , 1997, 96, 526-534.	1.6	671
848	Augmented Peripheral Chemosensitivity as a Potential Input to Baroreflex Impairment and Autonomic Imbalance in Chronic Heart Failure. <i>Circulation</i> , 1997, 96, 2586-2594.	1.6	221
849	Heart rhythms, ventricular arrhythmias, and death in chronic heart failure. <i>Journal of Cardiac Failure</i> , 1996, 2, 177-183.	0.7	25
850	Reproducibility of Heart Rate Variability Indices during Exercise Stress Testing and Inotrope Infusion in Chronic Heart Failure Patients. <i>Clinical Science</i> , 1996, 91, 87-88.	0.0	16
851	Reproducibility of Heart Rate Variability Measures in Patients with Chronic Heart Failure. <i>Clinical Science</i> , 1996, 91, 391-398.	1.8	31
852	Transient autonomic dysfunction precedes ST-segment depression in patients with syndrome X. <i>American Journal of Cardiology</i> , 1996, 77, 942-947.	0.7	28
853	Detection and significance of a discrete very low frequency rhythm in RR interval variability in chronic congestive heart failure. <i>American Journal of Cardiology</i> , 1996, 77, 1320-1326.	0.7	61
854	Contribution of peripheral chemoreceptors to ventilation and the effects of their suppression on exercise tolerance in chronic heart failure. <i>Heart</i> , 1996, 76, 483-489.	1.2	56
855	Role of catecholamines and sympathetic activation as a risk factor for coronary artery disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1995, 2, 222-228.	1.5	13
856	Role of Catecholamines and Sympathetic Activation as a Risk Factor for Coronary Artery Disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1995, 2, 222-228.	3.1	7
857	P-wave signal-averaged electrocardiogram in patients with idiopathic mitral valve prolapse syndrome and supraventricular arrhythmias. <i>International Journal of Cardiology</i> , 1995, 50, 175-180.	0.8	10
858	Abnormal autonomic control of the cardiovascular system in syndrome X. <i>American Journal of Cardiology</i> , 1994, 73, 1174-1179.	0.7	95
859	The effect of digoxin on the serum potassium concentration. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1993, 53, 187-189.	0.6	8
860	The Role of Pharmacological Treatment in the Chemoreflex Modulation. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	6